The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index; 159 of the 387 sources its claims cite were checked for support.
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Open accessAbstract
Compulsive drug seeking that is associated with addiction is hypothesized to follow a heuristic framework that involves three stages (binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation) and three domains of dysfunction (incentive salience/pathologic habits, negative emotional states, and executive function, respectively) via changes in the basal ganglia, extended amygdala/habenula, and frontal cortex, respectively. This review focuses on neurochemical/neurocircuitry dysregulations that contribute to hyperkatifeia, defined as a greater intensity of negative emotional/motivational signs and symptoms during withdrawal from drugs of abuse in the withdrawal/negative affect stage of the addiction cycle. Hyperkatifeia provides an additional source of motivation for compulsive drug seeking via negative reinforcement. Negative reinforcement reflects an increase in the probability of a response to remove an aversive stimulus or drug seeking to remove hyperkatifeia that is augmented by genetic/epigenetic vulnerability, environmental trauma, and psychiatric comorbidity. Neurobiological targets for hyperkatifeia in addiction involve neurocircuitry of the extended amygdala and its connections via within-system neuroadaptations in dopamine, enkephalin/endorphin opioid peptide, and γ-aminobutyric acid/glutamate systems and between-system neuroadaptations in prostress corticotropin-releasing factor, norepinephrine, glucocorticoid, dynorphin, hypocretin, and neuroim…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
159 of 387 cited sources checked · 88 supported · 2 flagged · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In postmortem brains of humans with AUD, nociceptin mRNA decreased in the amygdala (Kuzmin et al., 2009).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Nociceptin
What the sources say
- Disputedcites Kuzmin et al., 2009 sourceExperimental — accuracy not yet measured
The Results (section 2; page not provided) report lower pronociceptin (PNOC) mRNA in the hippocampus, with no evident PNOC difference in the other regions analyzed, including the central amygdala. The mRNA found to be lower in the central amygdala was for the nociceptin receptor (OPRL1), not nociceptin. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Indeed, there is a positive association between pain severity and a higher risk for AUD (Lawton and Simpson, 2009;Edlund et al., 2013).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Not checked — no full text of the sourcecites Lawton and Simpson, 2009 source
- Disputedcites Edlund et al., 2013 sourceExperimental — accuracy not yet measured
The Methods (2.2 Measures; page unavailable) say that pain severity was tested but was not statistically significant after controlling for days with pain and depression. The Discussion (section 4; page unavailable) reports a positive association for pain frequency—not severity—with alcohol abuse/dependence. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Note that a similar theoretical framework has been proposed for compulsive eating, in which habitual overeating, overeating to relieve a negative emotional state, and overeating despite aversive consequences reflect the three functional domains that are outlined in drug addiction (Moore et al., 2017(Moore et al., , 2019)).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in Humans
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hyperkatifeia can be considered an emotional parallel to hyperalgesia (i.e., greater sensitivity to physical pain) that is observed with repeated administration of chronic opioids and alcohol (Shurman et al., 2010;Koob, 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
- Partly supportedcites Shurman et al., 2010 sourceExperimental — accuracy not yet measured
The Introduction describes hyperkatifeia as hypersensitivity to emotional distress, analogous to hyperalgesia as hypersensitivity to pain. It links both to excessive opioid exposure that disrupts homeostasis, but says they are less likely when opioids effectively relieve pain. Our copy does not extend this pairing to repeated alcohol administration. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Koob, 2019 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Using the Addictions Neuroclinical Assessment, five subdomains of negative emotional states that can be operationally measured in human laboratory settings and paralleled by animal models were outlined (Kwako et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in Humans
What the sources say
- Partly supportedcites Kwako et al., 2016 sourceExperimental — accuracy not yet measured
The Introduction’s ANA Domains section identifies negative emotionality as one of three main domains and discusses measurable features such as dysphoria and hypohedonia. The Introduction also says the framework draws on humans and model organisms. Our copy does not outline five subdomains of negative emotional states or establish that each has a human-laboratory measure paralleled by an animal model (pages not provided). (LLM, conf=0.86)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Direct statistical intergroup comparisons and an analysis of changes in hub status indicated a reshaping of networks that are known to process information of negative valence.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in a Molecular-Neurocircuitry Study in an Animal Model
What the sources say
- Supportedcites Mechling et al., 2016 source
The Results and Discussion report that direct statistical comparison of control and Oprm1−/− mice found connectivity changes concentrated in pain- and aversion-related nodes, leading to a conclusion of predominant reshaping of networks that process negative-valence information. The same section says the hub analysis reached a similar conclusion. (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a subsequent study, the three neurofunctional domains that were proposed to be critical for the addiction cycle (incentive salience, negative emotionality, and executive function) were validated using a factor analysis of a deeply phenotyped clinical sample (Kwako et al., 2019; Fig. 3).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in Humans
What the sources say
- Partly supportedcites Kwako et al., 2019 sourceExperimental — accuracy not yet measured
The Results (Factor Structure) report that factor analysis identified three factors aligning well with the proposed domains in a clinical sample. But the Abstract (Conclusions) says the findings suggest the domains are relevant for AUD and that more work is required to validate and standardize their measures, so saying the domains were validated overstates the finding. (LLM, conf=0.84)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The negative valence network that evolved included such structures as the periaqueductal gray, hippocampus, amygdala, cingulate cortex, median raphe, and habenula (Mechling et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in a Molecular-Neurocircuitry Study in an Animal Model
What the sources say
- Partly supportedcites Mechling et al., 2016 sourceExperimental — accuracy not yet measured
The Results and Discussion identify the periaqueductal gray, hippocampal region, amygdala, anterior cingulate areas, and habenula among nodes with prominent connectivity changes in an aversion-related network. They identify the remaining region as the midbrain reticular nucleus (MRN), not the median raphe. The paper describes network reshaping after gene deletion, rather than a network that evolved. (LLM, conf=0.90)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The authors showed that m-opioid receptor gene (Oprm1) inactivation produced dramatic changes in aversion/ pain-related connectivity and less so in reward connectivity (Mechling et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in a Molecular-Neurocircuitry Study in an Animal Model
What the sources say
- Supportedcites Mechling et al., 2016 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Dopaminergic function is also compromised during acute alcohol withdrawal in animal models of chronic administration or compulsive-like drinking (Diana et al., 1993;Weiss et al., 1996).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neuroadaptations: Dopamine
What the sources say
- Not checked — no full text of the sourcecites Diana et al., 1993 source
- Supportedcites Weiss et al., 1996 source
The Ethanol withdrawal results report a progressive decline in accumbal dopamine during the eight hours after ethanol was removed from dependent rats exposed to a chronic ethanol diet. The Discussion likewise describes a withdrawal-associated fall in dopamine release. Page numbers are unavailable in our copy. (LLM, conf=0.93)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 136
- Probably not a substantial claim. 42
Every source the paper cites for this claim was checked and supports it.
In the paper
“Clinical, behavioral, and self-report measures of addiction, personality, cognition, behavior, and exposure to early life stress were collected as part of a screening and natural history study of AUD in 454 individuals who represented the spectrum of alcohol use and AUD.A three-factor model generally demonstrated a good fit with the assessment measures, and the factors closely aligned with the Add”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Validation of the Hyperkatifeia Construct in Humans
What the sources say
- Supportedcites Kwako et al., 2019 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The extended amygdala has long been hypothesized to play a key role in fear, anxiety, and stress (Le Doux, 2000;Shackman and Fox, 2016) and also in the emotional component of pain processing (Neugebauer et al., 2004).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Between-System Neurocircuits
What the sources say
- Not matchedcites Le Doux, 2000
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Shackman and Fox, 2016 source
In the section “The central extended amygdala responds to a broad spectrum of threats” (page unavailable), our copy describes the central extended amygdala as important for fear and anxiety and links its activity to the stress-sensitive hormone cortisol during threatening exposure. Shackman and Fox are cited for the fear, anxiety, and stress portion of the sentence; the pain-processing portion is attributed to Neugebauer et al. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites Neugebauer et al., 2004 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mutant mice that lacked arrestin 3 (b-arrestin 2) exhibited greater analgesia but significantly less antinociceptive tolerance, physical dependence, constipation, and respiratory suppression in response to morphine (Raehal and Bohn, 2014).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Within-System Neuroadaptations: Enkephalin/ Endorphin Opioid Peptides
What the sources say
- Partly supportedcites Raehal and Bohn, 2014 sourceExperimental — accuracy not yet measured
Section 7 states that mice lacking β-arrestin2 have enhanced morphine analgesia and less antinociceptive tolerance, physical dependence, constipation, and respiratory suppression. It qualifies the dependence finding: dependence is reduced at lower morphine doses, but at high doses it is indistinguishable from that in wild-type mice. The claim omits that dose limitation. (LLM, conf=0.87)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In animal models, early studies showed that precipitated opioid withdrawal decreases extracellular dopamine levels in the NAc and mesolimbic dopamine system (Pothos et al., 1991;Rossetti et al., 1992) and decreases dopamine neuron firing in the VTA (Diana, 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neuroadaptations: Dopamine
What the sources say
- Not checked — no full text of the sourcecites Pothos et al., 1991 source
- Not checked — no full text of the sourcecites Rossetti et al., 1992 source
- Partly supportedcites Diana, 2011 sourceExperimental — accuracy not yet measured
In “Dopamine as a Possible Therapeutic Target” (page unavailable), the paper reports reduced dopamine-neuron activity after morphine withdrawal in rats. It does not specify that the opioid withdrawal was precipitated or explicitly locate that firing reduction in the VTA. The extracellular-dopamine portion of the citing sentence is attributed to other citations, not Diana (2011). (LLM, conf=0.82)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with the hypothesis of blunted glucocorticoids in the HPA and sensitized CRF in the CeA, chronic glucocorticoid receptor blockade with mifepristone, when administered systemically during the course of alcohol vapor exposure, prevented the escalation of alcohol intake and blocked the increase in progressive-ratio responding for alcohol in dependent animals (Vendruscolo et al., 2012).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Between-System Neuroadaptations: Glucocorticoids
What the sources say
- Supportedcites Vendruscolo et al., 2012 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For alcohol, an increase in prodynorphin mRNA expression is observed in the CeA during acute withdrawal (Kissler et al., 2014) and in the NAc during withdrawal after 1 month of voluntary alcohol consumption (Przewłocka et al., 1997).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Between-System Neuroadaptations: Dynorphin/k-Opioid Receptors
What the sources say
- Partly supportedcites Kissler et al., 2014 sourceExperimental — accuracy not yet measured
The Results section reports increased DYN A-like immunoreactivity in the CeA of alcohol-dependent rats euthanized during acute withdrawal. It measured peptide immunoreactivity, not prodynorphin mRNA expression. The NAc finding is attached to a different citation in the citing sentence and is not attributed to Kissler et al. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites Przewłocka et al., 1997 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Vasopressin is a neurohormone that is synthesized in the hypothalamus and transported to the posterior pituitary (Brownstein et al., 1980), where it is released into the bloodstream during dehydration to act via vasopressin V 2 receptors on the kidneys to produce water retention (Kaufmann et al., 2000).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > E. Between-System Neuroadaptations: Vasopressin
What the sources say
- Not checked — no full text of the sourcecites Brownstein et al., 1980 source
- Partly supportedcites Kaufmann et al., 2000 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) states that vasopressin activates V2 receptors in renal collecting ducts, causing water retention. It does not address release into the bloodstream during dehydration. The hypothalamus-to-posterior-pituitary portion is cited to Brownstein et al., not Kaufmann et al. (LLM, conf=0.87)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“k-Opioid receptor antagonists do not block the acute rewarding (”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Between-System Neuroadaptations: Dynorphin/k-Opioid Receptors
What the sources say
- Partly supportedcites Schlosburg et al., 2013 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not matchedcites Zhou et al., 2013b
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In dependent rats, the a 1 -adrenergic receptor antagonist prazosin selectively blocked the increase in drinking that was associated with acute withdrawal (Walker et al., 2008), and the b-adrenergic receptor antagonist propranolol blocked the increase in drinking that was associated with acute withdrawal in dependent rats at doses that did not block nondependent drinking (Gilpin and Koob, 2010).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Between-System Neuroadaptations: Norepinephrine
What the sources say
- Not matchedcites Walker et al., 2008
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Gilpin and Koob, 2010 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“k-Opioid receptor agonists (administered systemically) and dynorphins (administered intracerebrally) produce aversive-like effects in both animals and humans (Shippenberg et al., 2007) and have been hypothesized to mediate negative emotional states that are associated with drug withdrawal (Chavkin and Koob, 2016), pain, and more specifically pain that is associated with acute withdrawal (see also”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Between-System Neuroadaptations: Dynorphin/k-Opioid Receptors
What the sources say
- Partly supportedcites Shippenberg et al., 2007 sourceExperimental — accuracy not yet measured
The discussion before §3 (page unavailable) says κ-opioid receptor agonists produce dysphoria in humans and aversive effects in experimental animals; it also reports conditioned aversion after systemic administration in animals. It does not establish that intracerebrally administered dynorphins produce aversive effects in both animals and humans. The later claim about negative emotional states is attached to a different citation, so it is not judged here. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites Chavkin and Koob, 2016 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“For alcohol, intracerebroventricular nociceptin administration significantly reduced the expression of somatic withdrawal signs and reversed anxiety-like behaviors that were associated with both chronic and acute alcohol intoxication in Wistar rats (Economidou et al., 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Nociceptin
What the sources say
- Supportedcites Economidou et al., 2011 source
The Results for Experiment 1 report significantly reduced somatic withdrawal scores after intracerebroventricular N/OFQ. The Discussion reports reduced anxiety-like responses following both chronic and acute ethanol intoxication, and Materials and Methods identifies the subjects as male Wistar rats. No page numbers are available in our copy. (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similar effects on dependenceinduced drinking in rats and binge-like drinking in mice were observed with injections of NPY in the amygdala, BNST, and NAc shell but not in the hypothalamus, suggesting a focus of the effects of NPY on alcohol drinking on the extended amygdala (Kelley et al., 2001;Gilpin et al., 2008;Pleil et al., 2015).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Neuropeptide Y
What the sources say
- Not checked — no full text of the sourcecites Kelley et al., 2001 source
- Partly supportedcites Gilpin et al., 2008 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites Pleil et al., 2015 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The blockade of glial cell activation restored mesolimbic dopamine function using minocycline (Taylor et al., 2016), prevented withdrawal using various inhibitors of glial cell activation (Watkins et al., 2009), prevented the relapse of morphine-seeking behavior via the epigenetic reprogramming of interleukin-10 overexpression (Schwarz et al., 2011), and prevented incubation-induced heroin seeking”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Supportedcites Taylor et al., 2016 source
Only the minocycline clause is attributed to Taylor et al. In the Results section, the paper reports that inhibiting microglial activation with minocycline restored cocaine place preference in opioid-dependent animals. The Introduction frames this restored reward processing as addressing disrupted mesolimbic dopamine function; the paper demonstrates it through reward behavior rather than a direct dopamine-function measure. (LLM, conf=0.88)
- Partly supportedcites Watkins et al., 2009 sourceExperimental — accuracy not yet measured
The Watkins et al. citation is attached only to the withdrawal claim, not the separately cited dopamine or morphine-seeking claims. The References (page unavailable) list a study reporting reduced opioid withdrawal with the glial modulator ibudilast, and the Concluding remarks predict suppression of opioid dependence. Neither establishes that glial-activation inhibitors prevent withdrawal altogether. (LLM, conf=0.85)
- Supportedcites Schwarz et al., 2011 source
The Introduction reports that neonatal handling increased IL-10 expression, attenuated glial activation, and prevented reinstatement of morphine conditioned place preference; it attributes the lasting IL-10 increase to decreased methylation of the IL-10 gene in microglia. The Results also report that the glial modulator ibudilast blocked reinstatement of morphine-seeking behavior. The other effects in the citing sentence are attributed to other citations, not Schwarz et al. (LLM, conf=0.89)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The acute administration of opioids exerts anti-inflammatory effects (Eisenstein, 2019), whereas chronic opioid exposure activates microglia and astrocytes in the spinal cord (Watkins et al., 2009;Cahill et al., 2016) and central nervous system, including the VTA, NAc, frontal cortex, and periaqueductal gray (Hao et al., 2011;Taylor et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Supportedcites Eisenstein, 2019 source
Eisenstein (2019) is cited for the acute-administration clause, not the chronic-exposure clause, which has separate citations. In “Effect of Opioids on Macrophages, Microglia, and Macrophage/Microglial-Derived and T Cell-Derived Cytokines and Other Inflammatory Associated Mediators” (page unavailable), the review reports that acute morphine administration reduced pro-inflammatory cytokine responses in macrophages, supporting the attributed anti-inflammatory effect. (LLM, conf=0.90)
- Supportedcites Watkins et al., 2009 source
Watkins et al. are cited for the spinal-cord glial-activation clause, not the acute anti-inflammatory effect or the named brain regions, which have separate citations. In “Beyond pathological pain: glial modulation of opioid actions” (page not provided), the review reports opioid-induced glial activation and morphine-induced increases in microglial and astrocytic activation markers; its cited studies include spinal inflammatory responses associated with chronic morphine exposure. (LLM, conf=0.88)
- Could not verifycites Cahill et al., 2016 sourceExperimental — accuracy not yet measured
Cahill et al. is cited for the spinal-cord portion of the sentence, not the acute anti-inflammatory effect or the other named brain regions. The 'Allostatic Processes in the VTA' section discusses activated microglia after prolonged morphine exposure, and the References list includes work on spinal astrocytes, but the passages found do not state that chronic opioid exposure activates both microglia and astrocytes in the spinal cord (searched: spinal cord, glial activation, microglia and astrocytes). (LLM, conf=0.72)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here, microglia via a BDNF-potassium-chloride transporter member 5 mechanism are hypothesized to be activated during opioid withdrawal and increase VTA GABAergic tone, which inhibits dopaminergic neurons (Cahill et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Supportedcites Cahill et al., 2016 source
In “Allostatic Processes in the VTA” (page unavailable), the paper proposes activated microglia as a source of BDNF during abstinence after prolonged morphine use and describes a BDNF–KCC2 pathway that makes VTA GABAergic neurons more excitable. The same section describes GABAergic input as inhibiting VTA dopamine neurons. The citing sentence presents this combined mechanism as a hypothesis, consistent with the paper’s wording. (LLM, conf=0.88)
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both stress and chronic pain activate microglia, increase Toll-like receptor 4 (TLR4) danger signals, increase the expression of nuclear factor kB target genes, and increase tumor necrosis factor a”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Partly supportedcites Watkins et al., 2007 sourceExperimental — accuracy not yet measured
The discussion of neuron-to-glia signals (page not provided) says nerve injury is associated with CNS TLR4 upregulation and TNF production, and the discussion of glial activation says inflammation or injury activates spinal microglia. These passages support parts of the chronic-pain claim, but they do not establish that stress produces the same changes or that either condition increases NF-κB target-gene expression. The paper discusses danger signals detected by TLRs, not an increase in those signals under both conditions. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Graeber, 2010 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, TLR4 knockdown in the amygdala reduced responding for alcohol in alcoholdependent rats (Liu et al., 2011), consistent with the hypothesis that the activation of innate immune danger signals within the amygdala may contribute to hyperkatifeia that drives dependence-induced alcohol drinking.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Partly supportedcites Liu et al., 2011 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For alcohol, chronic alcohol exposure increases brain 2-AG (Caillé et al., 2007;Alvarez-Jaimes et al., 2009) and N-arachidonoylethanolamine (AEA), particularly in basal forebrain areas, in rodents (González et al., 2004;Vinod et al., 2006), but decreases in both 2-AG and AEA were observed in the CeA during withdrawal (Serrano et al., 2018).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Endocannabinoids
What the sources say
- Partly supportedcites Caillé et al., 2007 sourceExperimental — accuracy not yet measured
Caillé et al. is cited for the increase in 2-AG, not for the sentence’s AEA or withdrawal claims. The Results section, “Ethanol, heroin, and cocaine self-administration induce specific alterations in NAc shell eCB levels” (page not available), reports increased extracellular 2-AG during an ethanol self-administration session. But “Baseline dialysate AEA and 2-AG levels are unaltered as a function of previous drug self-administration history” (page not available) reports no baseline 2-AG increase after repeated exposure, so the paper does not establish a sustained increase from chronic alcohol exposure. (LLM, conf=0.88)
- Partly supportedcites Alvarez-Jaimes et al., 2009 sourceExperimental — accuracy not yet measured
The Introduction and Discussion report increased extracellular 2-AG in the nucleus accumbens during ethanol self-administration by Wistar rats. They do not establish that chronic alcohol exposure increases brain 2-AG. The AEA and CeA-withdrawal claims are attached to other citations, not this paper. (LLM, conf=0.85)
- Partly supportedcites Serrano et al., 2018 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that CeA 2-AG decreased during 12 hours of abstinence in alcohol-dependent rats. They report no effect of alcohol history or sampling time on CeA AEA levels, so the claim that AEA also decreased during withdrawal is not supported. The earlier increases elsewhere in the brain are attributed to other citations in the citing sentence. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both FAAH inhibitors and MAGL inhibitors, which functionally increase endocannabinoids, decreased withdrawal-induced anxiety-like behavior and decreased alcohol consumption in alcoholdependent rats (Serrano et al., 2018).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Endocannabinoids
What the sources say
- Partly supportedcites Serrano et al., 2018 sourceExperimental — accuracy not yet measured
The results on anxiety-like behavior report improvement with the MAGL inhibitor MJN110 in alcohol-dependent rats, and the discussion says both MAGL and FAAH inhibitors ameliorated dependence-associated anxiety-like behavior. The alcohol-intake results report a significant reduction with MJN110, but the discussion states that FAAH inhibition did not consistently alter alcohol consumption in dependent rats or mice. Thus, the claim overstates the alcohol-consumption finding for FAAH inhibitors (sections on anxiety-like behavior, FAAH inhibition, and 2-AG clearance inhibition; page unavailable). (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It has also been hypothesized to normalize stress function and attenuate hyperkatifeia in the context of addiction (Lee and Weerts, 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Oxytocin
What the sources say
- Supportedcites Lee and Weerts, 2016 source
The ‘Oxytocin and stress’ section (page unavailable) proposes that oxytocin may normalize HPA-axis function and reduce anxiety and craving relevant to drug and alcohol use. The paper also summarizes evidence that it may attenuate withdrawal-associated negative mood and symptoms. Together, these support the citing sentence’s hypothesis, although the paper does not use the term ‘hyperkatifeia.’ (LLM, conf=0.88)
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✗ Asserted: fails✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Oxytocin also reduced cue-induced reinstatement in dependent rats but not in nondependent rats (Hansson et al., 2018).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Oxytocin
What the sources say
- Supportedcites Hansson et al., 2018 source
The Animal Studies section reports that oxytocin significantly decreased cue-induced reinstatement of alcohol seeking in dependent rats but had no effect on the reinstatement response in non-dependent rats. The Abstract states the same distinction. (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Naloxone-precipitated morphine withdrawal in rats that were chronically treated with morphine increased Hcrt-1 gene expression and Hcrt neuron activation in the lateral hypothalamus, and an Hcrt-1 receptor antagonist attenuated the somatic expression of naloxone-precipitated morphine withdrawal (Laorden et al., 2012).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > F. Between-System Neuroadaptations: Hypocretin
What the sources say
- Supportedcites Laorden et al., 2012 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For alcohol, NPY administration directly in the brain blocked the increase in self-administration in alcoholpreferring rats and in alcohol dependence, blocked the transition to excessive drinking with the development of dependence, and blocked the increase in GABA release in the CeA that was produced by alcohol”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Neuropeptide Y
What the sources say
- Not checked — no full text of the sourcecites Gilpin et al., 2003 source
- Partly supportedcites Gilpin et al., 2008 sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) reports that NPY infused into the CeA abolished dependence-induced increases in operant alcohol responding; it also describes prior findings of reduced drinking in alcohol-preferring rats. But NPY was given after dependence developed, so this study did not show that it blocked the transition to excessive drinking. The Discussion says the effect on CeA GABA transmission is a hypothesis, not a demonstrated block of alcohol-induced GABA release. (LLM, conf=0.91)
- Partly supportedcites Gilpin et al., 2011 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In heroin users during abstinence in a double-blind placebocontrolled study, acute intranasal oxytocin administration reduced craving and withdrawal scores and decreased cortisol levels but did not significantly change anxiety (Moeini et al., 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Oxytocin
What the sources say
- Supportedcites Moeini et al., 2019 source
The Abstract describes a randomized, double-blind, placebo-controlled trial of a single intranasal oxytocin dose in heroin-dependent men during abstinence. It reports reduced craving and withdrawal scores, decreased cortisol, and no significant change in anxiety; the Results section confirms the craving, withdrawal, and anxiety findings. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For alcohol, women are more likely to experience blackouts, liver inflammation, brain atrophy, cognitive deficits, certain cancers, negative affect during withdrawal, and stress-or anxiety-induced relapse (Becker and Koob, 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Partly supportedcites Becker and Koob, 2016 sourceExperimental — accuracy not yet measured
The Withdrawal/Negative Affect section (page not available) reports more rapid alcoholic liver disease and neurotoxicity in women, while the Preoccupation/Anticipation section reports greater stress-induced relapse risk for women with alcohol use. The copy does not establish the specific claims about blackouts, liver inflammation, brain atrophy, cognitive deficits, or cancers. Its evidence about longer-lasting negative affect concerns adolescent girls after heavy drinking, not specifically withdrawal; it also does not establish anxiety-induced relapse separately from stress-induced relapse. (LLM, conf=0.86)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic alcohol exposure and withdrawal result in modest elevations of alcohol intake in male High Alcohol Preferring 2 mice.In contrast, female High Alcohol Preferring 2 mice did not show changes in alcohol intake (Lopez et al., 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Supportedcites Lopez et al., 2011 source
The Results section for Experiment 2 reports increased ethanol intake in male HAP-2 mice after chronic ethanol exposure and withdrawal, while HAP-2 females showed no change. The paper’s Abstract Results describes the male increase as modest, matching the claim. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Opioids are recognized as the most powerful and effective drugs for the relief of acute pain in humans, and a unifying common theme is their relief of pain and suffering, including negative emotional states (Lutz and Kieffer, 2013).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Partly supportedcites Lutz and Kieffer, 2013 sourceExperimental — accuracy not yet measured
The Introduction describes morphine as a highly potent, widely used painkiller and says opioid drugs have euphoric effects and influence mood. It does not establish that opioids are the most powerful and effective drugs specifically for acute pain in humans, or that opioids generally relieve negative emotional states; the paper describes distinct mood effects across opioid receptors. (LLM, conf=0.87)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A small study showed that intranasal oxytocin blocked alcohol withdrawal in humans, based on such measures as the Alcohol Withdrawal Symptom Checklist of the Clinical Institute Withdrawal Assessment for Alcohol, and reduced the amount of benzodiazepines that were required for treatment (Pedersen et al., 2013).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Oxytocin
What the sources say
- Supportedcites Pedersen et al., 2013 source
The Abstract Methods describe a small randomized trial (7 oxytocin recipients and 4 placebo recipients) that used both CIWA scores and the Alcohol Withdrawal Symptom Checklist; these are separate measures. The Abstract Results report lower withdrawal scores and substantially less lorazepam required with oxytocin, while the Conclusions say the treatment may block alcohol withdrawal. (LLM, conf=0.92)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, opioids are significantly less effective against chronic pain, such as neuropathic pain, fibromyalgia, and low-back pain, and tolerance develops to the analgesic effects of opioids, thus necessitating the need for increasingly higher doses to sustain analgesia (McQuay, 1988;Dowell et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Not matchedcites McQuay, 1988
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites Dowell et al., 2016 sourceExperimental — accuracy not yet measured
The Clinical Evidence Review (page not provided) says opioids provide moderate short-term pain relief and that tolerance can diminish response over time, while long-term benefit for chronic pain remains uncertain. It does not establish that opioids are significantly less effective for the three named conditions or that tolerance necessitates increasingly higher doses; the Recommendations instead advise reassessment when dose requirements escalate. (LLM, conf=0.85)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, for alcohol, the gaps between women and men are narrowing with regard to the prevalence, frequency, and intensity of drinking, early onset drinking, having AUD, drunk driving, and self-reported consequences (White et al., 2015;Slade et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Not checked — no full text of the sourcecites White et al., 2015 source
- Partly supportedcites Slade et al., 2016 sourceExperimental — accuracy not yet measured
The Methods (Data extraction) include drinking prevalence, frequency, amount consumed, age of onset, alcohol use disorder, and alcohol-related problems among the indicators examined. The Results (Pooled results from meta-analyses) find a narrowing male–female gap across the three broad indicator categories. Drink driving is mentioned as an example of a negative consequence, but the paper does not establish a narrowing gap for drink driving specifically. (LLM, conf=0.84)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Individuals who were in acute withdrawal (24-72 hours) from opioids or protracted abstinence (average of 30 months) exhibited lower pain thresholds and pain tolerance, measured by the ischemic pain submaximal tourniquet procedure, and these decreases in pain thresholds were exacerbated by negative emotional states (Carcoba et al., 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Partly supportedcites Carcoba et al., 2011 sourceExperimental — accuracy not yet measured
Methods §2.1 gives 24–72 hours since the last heroin dose and a mean 30.4 months of abstinence; §2.2 confirms the tourniquet procedure. Results §3.4 and the Discussion report reduced thresholds and tolerance during withdrawal, but the abstinent group’s heightened pain sensitivity appeared only on tolerance assessments. Negative pictures further reduced pain thresholds in the withdrawal group, not demonstrably in both groups. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, male rats also exhibit greater motivational signs of withdrawal, such as anxiety-like responses in the social interaction test (Varlinskaya and Spear, 2004) and elevated plus maze after one cycle of exposure to an alcohol liquid diet (Overstreet et al., 2004a), and greater increases in acoustic startle responses than female rats (Reilly et al., 2009).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Not checked — no full text of the sourcecites Varlinskaya and Spear, 2004 source
- Not matchedcites Overstreet et al., 2004a
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Reilly et al., 2009 source
The Reilly et al. citation is attached to the comparison of acoustic startle responses, not the social interaction or elevated plus maze findings, which have separate citations. The Discussion reports a consistent increase in startle reactivity during ethanol withdrawal in males, versus small to no changes in females and ovariectomized females. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In animal models, female rodents generally acquire morphine and heroin self-administration faster than males and exhibit higher motivation to self-administer opioids (Lynch and Carroll, 1999;Cicero et al., 2003;Becker and Koob, 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Not checked — no full text of the sourcecites Lynch and Carroll, 1999 source
- Not checked — no full text of the sourcecites Cicero et al., 2003 source
- Supportedcites Becker and Koob, 2016 source
In the Opiates subsection of “Animal Models,” the review states that females acquire morphine and heroin self-administration faster than males and show higher motivation to self-administer both drugs. This directly supports the attributed paraphrase. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“For alcohol, males generally exhibit a greater withdrawal response and slower recovery from acute alcohol withdrawal (Becker and Koob, 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Supportedcites Becker and Koob, 2016 source
In “Sex Differences in the Withdrawal/Negative Affect Stage,” the review states that males generally show a greater withdrawal response and slower recovery from acute alcohol withdrawal. Its examples concern animal models, including male and female rats. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The type of pain is likely important, as well as the dependent variable that is used to measure negative affective effects of pain, the time course of dynorphin mediation, and the opposing actions of dynorphin neuron subcircuits (Cahill et al., 2014;Massaly et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Partly supportedcites Cahill et al., 2014 sourceExperimental — accuracy not yet measured
The sections “DO KORs CONTRIBUTE TO PAIN AVERSIVENESS?” and “OPIOID RECEPTORS MODULATE PAIN AND REWARD” distinguish acute from chronic pain and discuss sustained dynorphin release, supporting the importance of pain type and time course. The paper also discusses measures of pain aversion, but its “KOR REGULATION OF MESOLIMBIC CIRCUITRY” section describes differing KOR effects across neural projections, not opposing actions of dynorphin-neuron subcircuits. The indexed passages provide no page numbers. (LLM, conf=0.83)
- Partly supportedcites Massaly et al., 2016 sourceExperimental — accuracy not yet measured
In “Pain and stress dysregulate the mesolimbic reward pathway” (page unavailable), the review says responses vary with the type of pain and pain paradigm. In “Dopamine and kappa opioid system in chronic pain and stress disorders” (page unavailable), it discusses differing behavioral measures and opposing effects of KOR activation in distinct nucleus accumbens regions. It does not specifically establish a time course for dynorphin’s mediation of pain-related negative affect or attribute those opposing effects to dynorphin neuron subcircuits. (LLM, conf=0.86)
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, in a study of chronic inflammatory pain that was induced by a hindpaw injection of Complete Freund's Adjuvant, dynorphin expression increased in dynorphin-containing neurons in a discrete subregion of the NAc shell through a disinhibition mechanism, and pain increased k-opioid receptor function (Massaly et al., 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Pain and Animal Models of Addiction
What the sources say
- Supportedcites Massaly et al., 2019 source
The Discussion (page not provided) states that pain increases dynorphin expression and recruits dynorphin-containing neurons in a discrete NAc shell subregion through disinhibition, and increases KOR function. The Methods (page not provided) confirm that the inflammatory-pain model used a hindpaw injection of Complete Freund’s Adjuvant. (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Alcohol withdrawal-induced hyperalgesia was also attenuated by a histone deacetylase inhibitor, suggesting possible epigenetic mechanisms (Pradhan et al., 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Supportedcites Pradhan et al., 2019 source
The Discussion reports that an HDAC inhibitor prevented withdrawal-induced mechanical hyperalgesia in rats and says this suggests epigenetic regulation. That supports the citing sentence’s hedged interpretation; the study does not establish a specific epigenetic mechanism. (LLM, conf=0.94)
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The local infusion of microgram amounts of the k-opioid receptor antagonist nor-BNI into the ventral NAc shell blocked conditioned place aversion and the lower motivation to self-administer sucrose that was produced by inflammation (Massaly et al., 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Partly supportedcites Massaly et al., 2019 sourceExperimental — accuracy not yet measured
The Results section on KORs and pain-induced negative affect reports that local norBNI prevented or reversed the inflammation-induced decrease in motivation to self-administer sucrose. The Results section on dynorphin-containing neurons reports that 4 μg of norBNI in the ventral NAc shell blocked real-time place aversion during inflammatory pain. That aversion was induced by photo-stimulation, not shown to be conditioned place aversion produced by inflammation; 2 μg did not prevent it after inflammation. (LLM, conf=0.89)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, individuals with comorbid pain and AUD may drink to alleviate pain-related negative affect, and behavioral treatments that improve pain-coping skills may enhance pain-management abilities, subsequently reducing coping-motivated drinking (Moskal et al., 2018).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Supportedcites Moskal et al., 2018 source
The Discussion’s Conclusions state that people with co-occurring pain may drink to alleviate pain-related negative affect. They also propose that interventions improving pain-coping skills may enhance pain management and reduce coping-motivated drinking. The cited paper presents this as a possibility, matching the claim’s cautious wording; page numbers were not provided in our copy. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The lateral habenula projects to the VTA, and its activation is known to decrease activity in VTA dopamine neurons (Hikosaka, 2010; see the Within-System Neuroadaptations section above).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Supportedcites Hikosaka, 2010 source
The Abstract states that lateral habenula neurons project to the VTA. The Reward-based decision-making section reports that electrical stimulation of the lateral habenula inhibits dopamine-neuron activity in the VTA; it describes the connection to those neurons as indirect. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moderate alcohol use was associated with positive painrelated outcomes (e.g., greater quality of life), but excessive drinking and AUD were associated with deleterious pain-related outcomes (e.g., greater pain severity; Zale et al., 2015).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Supportedcites Zale et al., 2015 source
The review’s Summary and Conclusions describes a possible curvilinear association: moderate consumption may be associated with positive chronic-pain outcomes, while excessive use and AUD may be associated with worse outcomes. The Effects of Pain on Alcohol Use section specifically names greater quality of life among people with chronic pain, and the Effects of Alcohol on Pain section reports greater pain severity among trauma patients with a history of AUD. The citing sentence presents these as associations, not causal effects. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Intraventricular and intranasal administration of melanocortin-4 receptor antagonists reduced thermal hyperalgesia in alcohol-dependent rats during withdrawal (Roltsch Hellard et al., 2017), and this effect appeared to be mediated by melanocortin-4 receptor signaling in the CeA (Avegno et al., 2018).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Not checked — no full text of the sourcecites Roltsch Hellard et al., 2017 source
- Supportedcites Avegno et al., 2018 source
The MC4Rs in CeA results section reports that an MC4R antagonist infused into the CeA rescued thermal hyperalgesia in alcohol-dependent rats during withdrawal. The Discussion likewise states that MC4R blockade in the CeA rescues alcohol withdrawal hyperalgesia, supporting the clause attributed to Avegno et al. (LLM, conf=0.93)
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Alcohol withdrawal-induced hyperalgesia and relapse-like alcohol consumption were reversed by the chemogenetic inhibition of lateral habenula neurons, the pharmacological activation of M-channels, and the overexpression of the M-channel subunit potassium voltage-gated channel subfamily KQT member 3 (Kang et al., 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Supportedcites Kang et al., 2019 source
The Abstract states that chemogenetic inhibition of lateral habenula neurons, pharmacological activation of M-channels, and KCNQ3 overexpression relieved hyperalgesia and decreased relapse-like alcohol consumption in alcohol-withdrawn rats. The Results section on KCNQ3 overexpression also reports increased paw-withdrawal latency and reduced ethanol intake. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Polymorphisms of the CRF binding protein (CRHBP) gene have also been associated with the risk of both heroin addiction in African Americans (Levran et al., 2014) and a higher risk of drinking and/or anxiety in subjects with AUD (Haass-Koffler et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
What the sources say
- Supportedcites Levran et al., 2014 source
The Discussion reports that CRHBP rs1875999 was associated with heroin addiction in the study’s African American sample. The association was nominal and did not survive correction for multiple testing. The drinking and anxiety clause is attributed to Haass-Koffler et al., not to Levran et al. (LLM, conf=0.91)
- Supportedcites Haass-Koffler et al., 2016 source
The Results section reports that CRHBP variants were associated with drinks per drinking day and anxiety measures in alcohol-dependent patients, and concludes that variation might alter the risk of drinking and/or anxiety. The heroin-addiction clause is attributed to Levran et al., not to this source. (LLM, conf=0.92)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Associations were found between SNPs of the NPY Y2 receptor (NPY2R) gene and alcohol dependence, alcohol withdrawal symptoms, tobacco addiction, comorbid alcohol and cocaine dependence, and cocaine dependence (Wetherill et al., 2008;Okahisa et al., 2009;Mutschler et al., 2012;Bhaskar et al., 2013).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
What the sources say
- Partly supportedcites Wetherill et al., 2008 sourceExperimental — accuracy not yet measured
The Abstract Results and Results > Association results report NPY2R SNP associations with alcohol dependence, withdrawal symptoms, comorbid alcohol and cocaine dependence, and cocaine dependence. The paper does not report an NPY2R association with tobacco addiction; that part of the sentence is not supported by this source. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites Okahisa et al., 2009 source
- Not checked — no full text of the sourcecites Mutschler et al., 2012 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Exposure to childhood trauma is a major risk factor for the development and maintenance of AUD (De Bellis, 2002) and predicts an earlier onset of heavy drinking (Waldrop et al., 2007;Enoch, 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
What the sources say
- Not checked — no full text of the sourcecites De Bellis, 2002 source
- Not checked — no full text of the sourcecites Waldrop et al., 2007 source
- Supportedcites Enoch, 2011 source
The section on early-onset problem drinking reports that childhood stressors predict earlier drinking onset and that childhood maltreatment increases the risk of adolescent binge drinking. The Conclusion describes a pathway from early-life stress through adolescent problem drinking to alcohol dependence. Although the citing sentence attaches De Bellis (2002) to the separate ‘major risk factor’ clause, Enoch (2011) supports the earlier-drinking point attributed to it. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, using this choice model, a study in rhesus monkeys failed to show positive effects with a CRF 1 receptor antagonist (although one of three monkeys did respond) and a k-opioid receptor antagonist, but it did show positive results with opioid substitution drugs (Negus and Rice, 2009).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Negative Results
What the sources say
- Supportedcites Negus and Rice, 2009 source
The Discussion’s “Effects of Antalarmin and GNTI” section reports that the kappa-opioid antagonist failed to suppress increased heroin choice in any monkey and the CRF1 antagonist was ineffective in two of three. The Results confirm a response to the CRF1 antagonist in the third monkey. The “Effects of morphine” section reports that morphine suppressed the withdrawal-associated increase in heroin choice and describes positive findings for other mu-opioid agonists from prior studies. (LLM, conf=0.91)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent epidemiological study showed particularly high comorbidity between AUD and major depressive disorder and bipolar disorder and comorbidity with personality disorders and anxiety disorders (Grant et al., 2015).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
What the sources say
- Supportedcites Grant et al., 2015 source
The Results (Comorbidity) report associations between AUD and major depressive disorder, bipolar I disorder, antisocial and borderline personality disorders, and several anxiety disorders. The Abstract (Results) describes the anxiety-disorder associations as modest, consistent with the citing sentence’s distinction between particularly high comorbidity with mood disorders and comorbidity with anxiety disorders. (LLM, conf=0.92)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In rodent studies, choice procedures are notoriously resistant to disruption, and a large proportion of rats continue to select a sweet solution (e.g., saccharin) rather than the drug even after the clear establishment of dependence (Lenoir et al., 2013;Ahmed, 2018).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Negative Results
What the sources say
- Partly supportedcites Lenoir et al., 2013 sourceExperimental — accuracy not yet measured
The Results (page unavailable) show that 8 of 20 rats with extended heroin access still preferred saccharin, and the Discussion describes markers of dependence in that group. But extended access also increased heroin preference from 25% to 60%, so describing the choice procedure as resistant to disruption without that qualification overstates this paper's finding. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Ahmed, 2018 source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In human studies, gabapentin blocked craving in a human laboratory study in non-treatment-seeking AUD subjects (Mason et al., 2009) and was shown to be an effective treatment of AUD in a double-blind placebo-controlled clinical trial (Mason et al., 2014).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Partly supportedcites Mason et al., 2009 sourceExperimental — accuracy not yet measured
The Abstract identifies a human laboratory study of non-treatment-seeking, alcohol-dependent participants, and the Discussion reports that gabapentin significantly attenuated several measures of cue-induced craving. “Blocked craving” overstates that result: the Results report no significant difference in general craving. The clinical-trial claim is attributed to Mason et al. (2014), not this source. (LLM, conf=0.84)
- Supportedcites Mason et al., 2014 source
The Mason et al. (2014) citation is attached to the treatment-trial finding, not the preceding claim about the 2009 laboratory study. The Introduction describes a double-blind, placebo-controlled trial, and the Abstract Results report improved abstinence and no-heavy-drinking rates; the Discussion concludes that gabapentin, particularly at 1800 mg, effectively treated alcohol dependence. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Both Hcrt-1 and Hcrt-2 receptor blockade decreased alcohol self-administration in alcohol-preferring rats(Lawrence et al., 2006;Brown et al., 2013).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Not checked — no full text of the sourcecites Lawrence et al., 2006 source
- Supportedcites Brown et al., 2013 source
The Introduction reports that selective OX1R blockade attenuated ethanol self-administration in ethanol-preferring rats. The section “Central OX2R antagonism reduces ethanol, but not sucrose self-administration” reports that both tested doses of the OX2R antagonist significantly reduced responding for ethanol. No page numbers are available in our copy. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A recent overall-negative study with a gabapentin prodrug has been reported, but the consensus was that the dose was low, and secondary analyses showed some efficacy in some subgroups of subjects in the study (Falk et al., 2019;Laska et al., 2020).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Partly supportedcites Falk et al., 2019 sourceExperimental — accuracy not yet measured
The Results report no significant overall benefit and identify statistically significant effects in some subgroups; the Discussion cautions that these subgroup findings could be spurious. The Discussion says a higher dose might have been needed, but also says the tested dose was within the range previously found efficacious for alcohol use disorder. It does not establish a consensus that the dose was low. (LLM, conf=0.88)
- Partly supportedcites Laska et al., 2020 sourceExperimental — accuracy not yet measured
The Introduction reports that the original gabapentin enacarbil trial found no significant difference from placebo, and the Discussion reports better outcomes for some subgroups in this reanalysis. The paper gives the dose as 600 mg twice daily but does not say there was a consensus that it was low. (LLM, conf=0.88)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For alcohol in animal models, alcohol self-administration in dependent rats prevented the manifestation of a withdrawal syndrome (Roberts et al., 1996) and reversed the hypodopaminergic effects of alcohol withdrawal (Weiss et al., 1996).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Not checked — no full text of the sourcecites Roberts et al., 1996 source
- Supportedcites Weiss et al., 1996 source
The Weiss et al. citation is attached to the claim that self-administration reversed withdrawal-related hypodopaminergia, not to the separate withdrawal-syndrome claim attributed to Roberts et al. In Weiss et al.'s Discussion (Figure 5), ethanol self-administration in dependent rats restored accumbal dopamine to prewithdrawal levels. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, opioid addiction has been hypothesized to be sustained by a learned association between opioids and relief from an existing dysphoric state, and this learned association is formed through negative reinforcement (Evans and Cahill, 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Supportedcites Evans and Cahill, 2016 source
In “Learned association of relief from aversion” (page not provided), the authors hypothesize that relief of dysphoric withdrawal states creates a learned association with opioid use. They explicitly describe that relief as negative reinforcement and propose that the association can later drive craving and relapse. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For alcohol, prepro-Hcrt mRNA increased in the lateral hypothalamus in inbred alcohol-preferring rats after chronic alcohol consumption(Lawrence et al., 2006) but decreased in the perifornical area in Sprague-Dawley rats(Morganstern et al., 2010).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Not checked — no full text of the sourcecites Lawrence et al., 2006 source
- Partly supportedcites Morganstern et al., 2010 sourceExperimental — accuracy not yet measured
The Results (Experiment 1; page not available) report that chronic ethanol consumption reduced OX mRNA in Sprague-Dawley rats. The measurement was in the perifornical lateral hypothalamus (PFLH), however, not the perifornical (PF) area separately; the paper’s separate LH-versus-PF analysis concerned acute ethanol. The claim about alcohol-preferring rats is attributed to a different citation and is not judged here. (LLM, conf=0.85)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With regard to non-alcohol-like drugs, acamprosate is one of three Food and Drug Administration-approved medications for the treatment of AUD that is widely prescribed worldwide, and it has an effect size (Mason, 2003;Maisel et al., 2013;Jonas et al., 2014) that is similar to selective serotonin reuptake inhibitors for depression (Schalkwijk et al., 2014).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Not checked — no full text of the sourcecites Mason, 2003 source
- Partly supportedcites Maisel et al., 2013 sourceExperimental — accuracy not yet measured
The Results (End-of-Treatment Outcomes; page unavailable) report effect sizes for acamprosate in treating alcohol use disorders, supporting the part of the sentence for which Maisel et al. is cited. The copy does not establish that acamprosate is one of three FDA-approved medications; the Discussion (Concluding Comments; page unavailable) says its effects are somewhat smaller than those of medications for depression, rather than establishing similarity to SSRIs. The SSRI comparison is separately cited to Schalkwijk et al. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites Jonas et al., 2014 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a human laboratory study of non-treatment-seeking subjects with AUD, mifepristone decreased alcoholcued craving in the laboratory and reduced alcohol consumption during the 1-week treatment phase and 1-week post-treatment phase (Vendruscolo et al., 2015).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Supportedcites Vendruscolo et al., 2015 source
The paper describes a human laboratory study of nontreatment-seeking, alcohol-dependent volunteers (Number 8 August 2015; page not specified). It reports significantly lower alcohol-cued craving after one week of mifepristone and fewer drinks per week during treatment and post-treatment follow-up than with placebo. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It also blocked hyperkatifeia-like responses in alcoholdependent rats and blocked dependence-induced drinking in rodents (Roberto et al., 2008).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Partly supportedcites Roberto et al., 2008 sourceExperimental — accuracy not yet measured
The Discussion reports that gabapentin blocked anxiety-like behavior after withdrawal from a single high ethanol dose, but that experiment did not test chronically alcohol-dependent rats. The Discussion also reports that gabapentin blocked dependence-induced increases in ethanol drinking in rats. Thus, the drinking finding is supported, while the claimed dependence status for the anxiety finding is not. (LLM, conf=0.88)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“consistent with the argument that stressful events during protracted abstinence can generalize to such a dysphoric state and produce recall that opioid drugs can relieve such a negative state (Koob, 2008;Evans and Cahill, 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Not matchedcites Koob, 2008
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Evans and Cahill, 2016 source
In “Learned association of relief from aversion,” the paper argues that opioid use becomes associated with relief of dysphoria and that a later negative life event—even after years of abstinence—can reactivate that association. It also describes stress-induced relapse as a generalization from drug relief of withdrawal-induced dysphoria. (LLM, conf=0.93)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“A heuristic framework for addiction includes a threestage cycle-binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation-that provides a starting point for exploring the relatively new construct of hyperkatifeia in the context of drug withdrawal (Koob and Le Moal, 1997;Koob, 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
What the sources say
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, negative reinforcement becomes the source of motivation for drug seeking as the individual works to reduce, terminate, or prevent the negative emotional state or hyperkatifeia of drug withdrawal.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“From a nosology perspective, substance use disorders are now considered spectrum disorders as described by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5; American Psychiatric Association, 2013), which provides a framework for the intensity of symptoms with regard to the number of symptoms that are presented by the individual.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
What the sources say
- Not matchedcites American Psychiatric Association, 2013
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In opioid addiction or OUD, drug use includes intense initial intoxication that is associated with intravenous or smoked drug intake, followed by the development of profound tolerance and the consequent escalation of intake.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Under this addiction framework, stage-related dysregulation occurs in three functional domains (incentive salience/ habits, negative emotional states, and executive function) that are mediated by three major neurocircuitry elements (basal ganglia, extended amygdala, and prefrontal cortex, respectively; Koob and Le Moal, 1997).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
What the sources say
- Not checked — no full text of the sourcecites Koob and Le Moal, 1997 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although all drugs of abuse have positive reinforcing properties, the termination of drug taking inevitably leads to negative emotional states of acute and protracted withdrawal in the withdrawal/negative affect stage, which generates a second motivational drive from negative reinforcement.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These three stages feed into each other, become more intense, and ultimately lead to the pathologic state of addiction or substance use disorder (Koob and Le Moal, 1997; Fig. 1).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
What the sources say
- Not checked — no full text of the sourcecites Koob and Le Moal, 1997 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The classic drugs of addiction are opioids and alcohol.The pattern of misuse for each encompasses most of the patterns that are observed with other drugs of abuse.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“An inability to obtain the drug and the resulting abstinence results in physical discomfort, somatic signs of withdrawal, and profound hyperkatifeia.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hyperkatifeia, which often precedes somatic signs of withdrawal, signals pronounced preoccupation with obtaining opioids (craving).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Under this framework in the withdrawal/negative affect stage, the manifestation of a withdrawal syndrome after the cessation of chronic drug administration can be defined not only in terms of the classic”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
None of the sources cited for this claim have been checked yet.
In the paper
“The two opposing responses are temporally linked (a triggers b), with the b-process subtracting the impact of the already existing a-process.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In fact, opponent process theory was not only argued to be a counteraction to the hedonic actions of drugs of abuse; it was also argued to be a general phenomenon that is associated with hedonic breaks with homeostasis, including fear conditioning, tonic immobility, ulcer formation, eating disorders, jogging, peer separation, glucose preference, and even skydiving (Solomon andCorbit, 1973, 1974;H”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Under this framework, the first, initial use of a drug triggers a primary affective process (a positive hedonic process), termed the”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“From the perspective of self-regulation theory, opponent process-driven hyperkatifeia sets up misregulation in which subjects take more drug to alleviate hyperkatifeia, which paradoxically drives more hyperkatifeia.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neurocircuits
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This resulting tolerance produces more drug taking to remove the b-process and thus engages the addictive cycle (Solomon and Corbit, 1974).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
- Not checked — no full text of the sourcecites Solomon and Corbit, 1974 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Little work has explored the neurobiological basis of opponent processes.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neurocircuits
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Early theorists argued that counteradaptations can explain the physiological (physical, somatic) effects of opioid withdrawal in the domain of body temperature (Himmelsbach, 1943;Martin, 1968).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
- Not matchedcites Himmelsbach, 1943
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Martin, 1968
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
In the paper
“Withdrawal from drugs of abuse is one symptom of what is defined symptomatically as substance use disorder in the DSM-5 and Drug Dependence in the International Statistical Classification of Diseases and Related Health Problems, 10th revision (World Health Organization, 1992).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
What the sources say
- Not matchedcites World Health Organization, 1992
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, from the perspective of negative reinforcement, drug seeking and craving that are associated with acute and protracted abstinence are key to the thesis outlined herein, in which somatic measures of withdrawal can be an index of dependence but do not always reflect the more motivational measures of withdrawal or hyperkatifeia.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“With repeated stimulation (e.g., drug taking), the b-process is strengthened so that it has a faster onset and greater intensity and takes longer to decay (Solomon and Corbit, 1974).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
- Not checked — no full text of the sourcecites Solomon and Corbit, 1974 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Notably, however, hyperkatifeiaassociated symptoms of withdrawal generally have an earlier onset and are manifested at lower doses of chronic drug intake.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Withdrawal from an alcohol binge or chronic high alcohol intake is characterized by a severe emotional and somatic withdrawal syndrome and intense craving for alcohol that is often driven by both negative emotional states and positive emotional states, similar to opioids.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“As discussed by Solomon and Corbit (1974), the quickest and possibly most effective way of removing the b-process is to produce the a-process by taking the drug again.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
- Not checked — no full text of the sourcecites Solomon and Corbit, 1974 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The notion of dependence on a drug, object, role, activity or any other stimulus-source requires the crucial feature of negative affect experienced in its absence.The degree of dependence can be equated with the amount of this negative affect, which may range from mild discomfort to extreme distress, or it may be equated with the amount of difficulty or effort required to do without the drug, obj”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
What the sources say
- Not matchedcites Russell, 1976
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
- Not matched
In the paper
“However, both somatic and psychologic symptoms are mediated by physiological changes in the body and brain, but the argument here is that the symptoms that are associated with hyperkatifeia have significantly more motivational significance than somatic signs of withdrawal (Koob, 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
What the sources say
- Not checked — no full text of the sourcecites Koob, 2019 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Later, counteradaptations were invoked to explain how the initial acute hedonic effects of a drug are opposed or counteracted by homeostatic changes in systems that mediate the primary effects of the drug (Solomon and Corbit, 1974;Siegel, 1975;Poulos and Cappell, 1991).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hypothesis in this review is that neural substrates of hyperkatifeia are a driving force of addiction, are multidetermined components of key motivational neurocircuits, and have been largely neglected in the search for pharmacotherapies for addiction.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The authors may not put it forward as true. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, this leads to further strengthening of the b-process and the necessity to increase the amount of drug that is needed to remove the b-process.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Several medications that target hyperkatifeia have been approved by the U.S. Food and Drug administration for the treatment of AUD and OUD.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Physical symptoms of withdrawal are reflected by signs and symptoms of a physical nature that are usually opposite to the acute effects of the drug itself.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Hyperkatifeia Versus Physical Withdrawal
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This hypernegative emotional state, termed hyperkatifeia, is hypothesized to sensitize with repeated drug exposure and withdrawal.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Here, the b-process presents as a negative emotional state and is described as intensely aversive (Solomon and Corbit, 1974).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Opponent Process
What the sources say
- Not checked — no full text of the sourcecites Solomon and Corbit, 1974 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Many individuals with AUD continue with a binge/withdrawal pattern for extended periods; for others, the pattern evolves into an opioid-like substance use disorder, in which they must have alcohol available at all times to avoid the consequences of abstinence (Koob et al., 2019).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Definition
What the sources say
- Not checked — no full text of the sourcecites Koob et al., 2019 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The unexpected delivery of rewards caused inhibition of the lateral habenula, consistent with an aversive role for activation of the habenula (Matsumoto and Hikosaka, 2007).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neurocircuits
What the sources say
- Not checked — no full text of the sourcecites Matsumoto and Hikosaka, 2007 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Chronic alcohol is well known to upregulate N-methyl-D-aspartate (NMDA) receptor function in the brain (Chandler et al., 1993;Snell et al., 1993;Roberto et al., 2004), including the upregulation of different NMDA receptor subunits with chronic alcohol and withdrawal in some brain regions (Trevisan et al., 1994;Follesa and Ticku, 1995).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Within-System Neuroadaptations: GABA and Glutamate
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition to the above within-system neuroadaptations, other neurocircuits appear to be activated by excessive drug intake that act in hedonic opposition to reward neurotransmitter circuits [corticotropinreleasing factor (CRF), norepinephrine, glucocorticoids, dynorphin, hypocretin, and neuroimmune factors] or act to protect against the development of hyperkatifeia (NPY, nociceptin, endocannabin”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > V. Between-System Neurobiological Substrates for Hyperkatifeia Associated with Opioid and Alcohol Withdrawal
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Key components of hyperkatifeia are dysphoria and malaise, reflected by a decrease in brain reward function and an increase in brain and hormonal stress responses.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neurocircuits
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“However, chronic alcohol decreases GABA receptor function, with multiple effects on GABA receptor subunits, including downregulation of the a1 subunit and upregulation of the a4 subunit (Mhatre et al., 1993;Devaud et al., 1997).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Within-System Neuroadaptations: GABA and Glutamate
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Much of the work on within-system neuroadaptations has focused on the mesolimbic dopamine system that projects from the VTA to the nucleus accumbens (NAc; Fig. 4).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neurocircuits
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“For opioids, the noncompetitive glutamate receptor antagonist MK-801 blocked the expression of withdrawal signs that were precipitated by naloxone in opioid-dependent animals (Tanganelli et al., 1991;Tokuyama et al., 1996), suggesting a hyperglutamatergic contribution to opioid withdrawal.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Within-System Neuroadaptations: GABA and Glutamate
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Acute alcohol potentiates receptor-activated cAMP production, but chronic exposure to alcohol decreases cAMPprotein kinase A activity and a decrease in cAMP response element binding protein (CREB) phosphorylation (Gordon et al., 1986).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Within-System Neuroadaptations: Enkephalin/ Endorphin Opioid Peptides
What the sources say
- Not checked — no full text of the sourcecites Gordon et al., 1986 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Finally, a local dynorphin circuit in the NAc has been hypothesized to be activated and ultimately contribute to the hypodopaminergic state of opioid and alcohol withdrawal (Carlezon et al., 2000).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neurocircuits
What the sources say
- Not checked — no full text of the sourcecites Carlezon et al., 2000 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For opioids at the neurocircuitry level, a prominent neuroadaptation is the loss of dopaminergic function in the mesolimbic dopamine pathway, which is hypothesized to contribute to hedonic tolerance and the hypohedonia that is associated with opioid withdrawal (see Fig. 4).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Within-System Neuroadaptations: Dopamine
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The k-opioid receptor agonist U50,488H suppressed dopamine release in the NAc in rats that self-administered heroin, resulting in an increase in immediate heroin intake (Xi et al., 1998).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Between-System Neuroadaptations: Dynorphin/k-Opioid Receptors
What the sources say
- Not matchedcites Xi et al., 1998
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“The vasopressin V 1B receptor antagonist SSR149415 blocked the heroin-and foot shock-induced reinstatement of heroin-seeking behavior, suggesting that vasopressin systems in the amygdala may be a key component of the aversive emotional consequences of opioid withdrawal (Zhou et al., 2008).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > E. Between-System Neuroadaptations: Vasopressin
What the sources say
- Not checked — no full text of the sourcecites Zhou et al., 2008 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, converging data from studies of CRF and norepinephrine suggest that both CRF and noradrenergic neurotransmission are enhanced during opioid and alcohol withdrawal, and CRF and noradrenergic functional receptor antagonists can block motivational aspects of opioid and alcohol withdrawal.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Between-System Neuroadaptations: Norepinephrine
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Whereas, acutely, opioid receptor agonists inhibit the HPA axis, opioid withdrawal potently activates it (Culpepper-Morgan and Kreek, 1997;Bearn et al., 2001).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Between-System Neuroadaptations: Glucocorticoids
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Dynorphin is an opioid peptide that binds k-opioid receptors.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Between-System Neuroadaptations: Dynorphin/k-Opioid Receptors
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“The V 1b receptor antagonist SSR149415 dose-dependently reduced the higher levels of alcohol self-administration that were observed in dependent animals, without affecting alcohol drinking in nondependent animals (Edwards et al., 2012a).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > E. Between-System Neuroadaptations: Vasopressin
What the sources say
- Not matchedcites Edwards et al., 2012a
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“The selective blockade of k-opioid receptor by 20 mg/kg nor-binaltorphimine (nor-BNI) administration (i.p.) 5 hours before naltrexone-precipitated withdrawal in morphine-dependent rats decreased some signs of opioid withdrawal during a 30-minute withdrawal session and, more relevant for the present thesis, decreased the subsequent conditioned place aversion for the withdrawal chamber 2 days later”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Between-System Neuroadaptations: Dynorphin/k-Opioid Receptors
What the sources say
- Not checked — no full text of the sourcecites Kelsey et al., 2015 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“For opioids, individuals with OUD, when subjected to acute withdrawal from heroin and methadone, exhibited persistent elevations of cortisol levels (Culpepper-Morgan and Kreek, 1997;Bearn et al., 2001), and cortisol levels correlated with withdrawal severity (Bearn et al., 2001).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Between-System Neuroadaptations: Glucocorticoids
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“High corticosterone decreases CRF mRNA in the PVN but increases CRF mRNA in the CeA and lateral BNST (Makino et al., 1994a,b;Albeck et al., 1997;Schulkin et al., 1998;Shepard et al., 2000).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Between-System Neuroadaptations: Glucocorticoids
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Injections of TNFa in the amygdala in rats increased anxiety-like behavior and mimicked the amplification of anxiety-like behavior that was observed with repeated cycles of alcohol drinking (Breese et al., 2008).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Not checked — no full text of the sourcecites Breese et al., 2008 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, the data suggest that, at least in rats, the modulation of endogenous endocannabinoids can reverse hyperkatifeia that is associated with opioid withdrawal, but the nature of such modulation may be circuitspecific.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Endocannabinoids
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Given that the activation of NPY in the CeA has opposite effects to CRF, one hypothesis is that NPY may act as a buffer to the stress-driving effects of CRF; by extrapolation, low functional activity of NPY may contribute to the etiology and vulnerability to hyperkatifeia.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Neuropeptide Y
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true. It may state two separate claims as one.
In the paper
“Neuropeptide Y has powerful orexigenic and anxiolytic-like effects in animal models and has been hypothesized to act in opposition to the actions of CRF in AUD and substance use disorders (Heilig and Koob, 2007).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Neuropeptide Y
What the sources say
- Not checked — no full text of the sourcecites Heilig and Koob, 2007 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, withdrawal from chronic drug exposure amplifies neuroimmune gene expression, impacting stress and fear circuits, and as a result is hypothesized to contribute to hyperkatifeia.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Nociceptin can block both opioid and alcohol withdrawal and attenuate the increase in alcohol and opioid self-administration in dependent animals.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Nociceptin
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, one hypothesis is that repeated alcohol intake may downregulate the endogenous nociceptin system, resulting in the activation of alcohol consumption through the release of stress modulation.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Nociceptin
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Endocannabinoids are hypothesized to have stressbuffering actions that may be involved not only in the response to repeated withdrawal from alcohol but also in the vulnerability to negative emotional dysregulation that drives excessive drinking.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Endocannabinoids
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the hypothesis is that repeated cycles of binge/withdrawal sensitize neuroimmune systems that interact with brain stress systems to facilitate negative emotional states during withdrawal and drive compulsive-like drinking under a negative-reinforcement framework.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true. It may state two separate claims as one.
- Rests on an assumption: The negative-reinforcement framework is valid for explaining compulsive-like drinking in dependence.
In the paper
“Mice that lacked TLR4 were protected from alcohol-induced glial activation, anxiety-like behavior, and cognitive impairments (Pascual et al., 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > G. Between-System Neuroadaptations: Neuroimmune Systems
What the sources say
- Not checked — no full text of the sourcecites Pascual et al., 2011 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a double-blind crossover study of non-treatment-seeking individuals with alcohol abuse, oxytocin did not produce an overall decrease in craving, but further analysis revealed that the effects on craving were moderated by attachment anxiety, with oxytocin reducing craving in more anxiously attached individuals and increasing craving in less anxiously attached individuals (Mitchell et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Oxytocin
What the sources say
- Not checked — no full text of the sourcecites Mitchell et al., 2016 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Dynorphin knockout mice exhibited a facilitated return to normal nociceptive baselines after a peripheral nerve lesion (Wang et al., 2001), suggesting a pronociceptive role for dynorphin in chronic pain, in contrast to the antinociceptive effects of acute k-opioid receptor agonist administration.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Not checked — no full text of the sourcecites Wang et al., 2001 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Hyperalgesia in the tail flick test that was associated with morphine withdrawal was blocked by microinjections of a CRF 1 /CRF 2 peptide receptor antagonist in the CeA, without affecting plasma corticosterone responses (McNally and Akil, 2002).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Not checked — no full text of the sourcecites McNally and Akil, 2002 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interwoven into this framework is that chronic opioids lose their effectiveness for chronic emotional pain.One could argue that chronic opioids actually drive chronic emotional pain via withdrawal.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Particularly important for the present thesis, opioids also relieve emotional pain, which is a key component of hyperkatifeia, as noted above, and the driving force for the withdrawal/negative affect stage of the addiction cycle.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“More men use and are addicted to opioids and alcohol (National Survey on Drug Use and Health, Substance Abuse and Mental Health Services Administration, 2007).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > VII. Hyperkatifeia and Sex Differences
What the sources say
- Not matchedcites National Survey on Drug Use and Health, Substance Abuse and Mental Health Services Administration, 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, individual differences beg the question of selective vulnerability in individuals who enter the addiction cycle via the withdrawal/negative affect stage (Fig. 6).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✗ Asserted: fails✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The authors may not put it forward as true. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Indeed, negative affect, measured by the Beck Depression Inventory, increased thermal and electrical sensation pain sensitivity in alcohol withdrawal, and depressed mood in patients was associated with lower pain tolerance (Jochum et al., 2010).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Not checked — no full text of the sourcecites Jochum et al., 2010 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Hyperalgesia that is associated with alcohol withdrawal can be blunted by the blockade of CRF 1 receptors (Edwards et al., 2012b), and CRF receptor antagonists can blunt nociceptive hypersensitivity in a wide variety of pain assays in animals (Hummel et al., 2010).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
- Not matchedcites Edwards et al., 2012b
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Hummel et al., 2010 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Much evidence shows that the activation of k-opioid receptor agonists elevates intracranial self-stimulation reward thresholds and decreases the function of the mesolimbic dopamine system (Todtenkopf et al., 2004;Chefer et al., 2013).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The threshold appeared to be a mean BAL of ;0.08% (i.e., the legal driving limit) for producing a small elevation of pain thresholds, and a significant reduction of pain intensity with a higher BAL was associated with greater pain insensitivity.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Theorists have long hypothesized that a negativereinforcement model of drug use assumes that individuals frequently consume alcohol (or opioids) to alleviate aversive physical or emotional states (Cappell and Herman, 1972;Sher and Levenson, 1982;Khantzian, 1985;Koob and Bloom, 1988;Baker et al., 2004;Ahmed and Koob, 2005).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Alcohol and Pain
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Melanocortin receptors also modulate nociceptin, opioid-induced analgesia, the development of tolerance to this effect, and opioid withdrawal-induced hyperalgesia (Kalange et al., 2007).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > A. Opioids and Pain
What the sources say
- Not checked — no full text of the sourcecites Kalange et al., 2007 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“With excessive use, these systems undergo neuroadaptations with chronic drug exposure that lower reward function, increase stress function, and increase the negative affect component of pain, all of which contribute to the construct of hyperkatifeia.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The opioid substitution drug methadone transiently blocks opioid self-administration in rats and dogs but not in monkeys (Jones and Prada, 1977;Mello et al., 1983;Leri et al., 2004;Alizadeh et al., 2018), and buprenorphine decreases opioid self-administration in dependent rats and monkeys (Mello et al., 1983;Chen et al., 2006).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A polymorphism of the oxytocin gene, rs6133010, was associated with alcohol dependence in a northern Chinese Han population (Yang et al., 2017).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
What the sources say
- Not checked — no full text of the sourcecites Yang et al., 2017 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“However, with chronic alcohol exposure and subsequent withdrawal, all of these epigenetic activities are reversed, with decreases in histone acetylation through an increase in histone deacetylase activity and decreases in the expression of BDNF, activity-related cytoskeleton-associated protein, and NPY in CeA circuitry that produce anxiety-like responses (Pandey et al., 2008a,b).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
What the sources say
- Not matchedcites Pandey et al., 2008a
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites Pandey et al., 2008b
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, these observations suggest that some measures of hyperkatifeia, such as the expression of stress-like responses in specific contexts and the escalation of drug taking in rodents, are sensitive to treatment with anti-hyperkatifeia agents, whereas other measures, such as choice procedures, may not be sensitive.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Negative Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The lifetime prevalence of DSM-IV substance dependence among people who began using drugs under the age of 14 was 34% and dropped to 14% for those who began using at age 21 or older (Grant and Dawson, 1998).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
What the sources say
- Not checked — no full text of the sourcecites Grant and Dawson, 1998 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“From a negative-reinforcement perspective, in a study cited above, rats showed avoidance of the cues that were paired with a hypothesized negative emotional state of precipitated opioid withdrawal, and this conditioned avoidance was blocked by a direct intracerebral injection of a peptide CRF antagonist in the CeA (Heinrichs et al., 1995).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
What the sources say
- Not checked — no full text of the sourcecites Heinrichs et al., 1995 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“One study reported negative results with one dose of a CRF 1 receptor small-molecule antagonist in a human laboratory study in reversing stress-induced craving but some efficacy in reversing HPA axis dysregulation (Schwandt et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Negative Results
What the sources say
- Not checked — no full text of the sourcecites Schwandt et al., 2016 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“For OUD, all medically assisted treatments that interact with the m-opioid receptor system (e.g., methadone and buprenorphine) reverse opioid withdrawal-induced hyperkatifeia in animal models and have established efficacy in treating opioid addiction (Mello and Mendelson, 1980).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Not checked — no full text of the sourcecites Mello and Mendelson, 1980 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Genetic association studies that have focused on neurobiological substrates for hyperkatifeia (CRF and other brain stress system) are limited, but some are listed below.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In adolescents who were homozygous for the C allele of the rs1876831 SNP of the CRF 1 receptor gene, a history of stress was associated with greater increases in future alcohol intake (Blomeyer et al., 2008;Schmid et al., 2010) and an earlier onset of drinking (Schmid et al., 2010).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“An association was found between binge drinking and single-nucleotide polymorphisms (SNPs) of the CRF 1 receptor gene in adolescents and alcohol-dependent adults (Treutlein et al., 2006), one of which, rs1876831, is located on an intron that could potentially influence CRF 1 receptor gene transcription.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > IX. Individual Differences in Hyperkatifeia
What the sources say
- Not checked — no full text of the sourcecites Treutlein et al., 2006 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the data on HPA axis endpoints confirmed target engagement by the tested dose and imply a dissociation between observation of the predicted endocrine effect without the predicted behavioral effect.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Negative Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Alcohol is commonly used in an effort to cope with symptoms, but in the end, it makes the prognosis worse, and comorbid mental health conditions complicate treatments for AUD (Mäkelä et al., 2015).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
What the sources say
- Not checked — no full text of the sourcecites Mäkelä et al., 2015 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Medications that have been developed to reverse the neurochemical changes outlined above would be hypothesized to be effective subjects when hyperkatifeia motivates drug seeking.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Development, Comorbidities, Epigenetics, and Hyperkatifeia
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“This study had a small sample size, was limited to only female subjects, and explored only one dose (Schwandt et al., 2016).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > B. Negative Results
What the sources say
- Not checked — no full text of the sourcecites Schwandt et al., 2016 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Acamprosate was developed from animal models of dependence-induced drinking (Le Magnen et al., 1987) and also blocked hyperkatifeia that was associated with alcohol withdrawal in rodent models (Cole et al., 2000).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“It has been argued that a 2 -adrenergic receptor agonists safely and effectively reduce symptoms of sympathetic overdrive and concomitant medication use during the treatment of alcohol withdrawal (Muzyk et al., 2011).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Not checked — no full text of the sourcecites Muzyk et al., 2011 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Methadone, buprenorphine, and other opioids are, however, substitution treatments, so they only transiently prevent hyperkatifeia while the drug in on board, but they do not reverse it.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This compulsive drug seeking defends a hedonic set point that gradually gains allostatic load and shifts from a homeostatic hedonic state to an allostatic hedonic state (Koob and Le Moal, 2001; Fig. 6).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Not matchedcites Koob and Le Moal, 2001
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
None of the sources cited for this claim have been checked yet.
In the paper
“Much of the clinical world recognizes the role of hyperkatifeia in driving addiction (Marlatt and Gordon, 1980;Khantzian, 1997Khantzian, , 2012Khantzian, , 2013)), but most preclinical medication development efforts to date have focused on blocking or modulating drug reward.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Not matchedcites Marlatt and Gordon, 1980
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Khantzian, 1997 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Most preclinical medication development efforts to date have focused on blocking or modulating drug reward.
- Not matched
In the paper
“Negative affect networks have been hypothesized to be activated not only during withdrawal but also by conditioned predictors of withdrawal (e.g., drug cues) and unappetitive consequences (e.g., punishment and frustrative nonreward) or their conditioned cues (Baker et al., 1987).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > D. Conditioning in Withdrawal and Protracted Abstinence
What the sources say
- Not matchedcites Baker et al., 1987
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
In the paper
“Gabapentin is a widely used off-label drug for AUD and is currently on the Veterans Administration formulary for the treatment of AUD (https://www. veteranshealthlibrary.va.gov/Encyclopedia/142,41564_VA; accessed August 10, 2020).”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
What the sources say
- Not matchedcites https://www. veteranshealthlibrary.va.gov/Encyclopedia/142,41564_VA
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Clearly, the opioid medication-assisted treatment of opioid addiction blocks hyperkatifeia in humans, but only while the drug is on board.”
§ Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development > C. Construct Validity
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
If the development of the b-process is blocked, then tolerance does not develop.
“Indeed, data indicate that if the dedvelopment of the bprocess is blocked, then tolerance does not develop.”
The paper relies on this without support.
Neurobiological findings from animal models of opioid and alcohol addiction are valid for understanding human hyperkatifeia and for developing medications for human addiction.
“The present review explores the rich neurobiology of hyperkatifeia in the context of animal models of opioid and alcohol addiction, with a focus on neuroadaptations that break with homeostasis and can possibly be reversed to facilitate recovery from addiction.”
The paper relies on this without support.
The negative-reinforcement framework is valid for explaining compulsive-like drinking in dependence.
“Thus, the hypothesis is that repeated cycles of binge/withdrawal sensitize neuroimmune systems that interact with brain stress systems to facilitate negative emotional states during withdrawal and drive compulsive-like drinking under a negative-reinforcement framework.”
The paper relies on this without support.
There is high comorbidity between chronic pain, addiction, depression, and suicide.
“The high comorbidity between chronic pain, addiction, depression, and suicide provides a compelling rationale for further studies in this domain.”
The paper relies on this without support.
Alcohol misuse correlates with poor mental health and often precedes diagnoses of mental health conditions.
“Alcohol misuse correlates with poor mental health and often precedes diagnoses of mental health conditions.”
The paper relies on this without support.
No double-blind treatment study of alcohol or opioid addiction has been conducted.
“No double-blind treatment study of alcohol or opioid addiction has been conducted.”
The paper relies on this without support.
Alcohol and opioids act directly on neurotransmitter systems associated with incentive salience and reward pathways and indirectly via GABA and glutamate systems to activate reward pathways.
“Alcohol and opioids act directly on neurotransmitter systems that are associated with incentive salience and reward pathways and indirectly via GABA and glutamate systems to activate reward pathways.”
The paper relies on this without support.
No single animal model is predictive of all aspects of the human condition.
“Given that no single animal model is predictive of all aspects of the human condition, future studies might engage human laboratory studies that capture the phenotype that is exhibited by the activation of negative-reinforcement circuits, and any positive results could be back-translated to animal models.”
The paper relies on this without support.
Gabapentin is an anticonvulsant Ca2+ channel blocker that increases GABAergic neurotransmission in the brain.
“Gabapentin is an anticonvulsant Ca 2+ channel blocker that increases GABAergic neurotransmission in the brain.”
The paper relies on this without support.
Alpha2-adrenergic receptor agonists block both somatic signs of withdrawal and anxiogenic-like responses to withdrawal in rodents.
“Additionally, a 2 -adrenergic receptor agonists block both somatic signs of withdrawal and anxiogenic-like responses to withdrawal in rodents.”
The paper relies on this without support.
In humans, alpha2-adrenergic receptor agonists clonidine and dexmedetomidine have been used extensively to treat acute alcohol withdrawal.
“In humans, the a 2adrenergic receptor agonists clonidine and dexmedetomidine have been used extensively to treat acute alcohol withdrawal.”
The paper relies on this without support.
Studies have reported hypersensitivity to pain and discomfort with opioids that can last for over 1 year post-detoxification, and hypersensitivity to pain is linked to the misregulation of alcohol consumption as a coping response.
“Studies have reported hypersensitivity to pain and discomfort with opioids that can last for over 1 year post-detoxification, and hypersensitivity to pain is linked to the misregulation of alcohol consumption as a coping response.”
The paper relies on this without support.
Most preclinical medication development efforts to date have focused on blocking or modulating drug reward.
“but most preclinical medication development efforts to date have focused on blocking or modulating drug reward.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1R expression in these key reward- and stress-related brain regions may contribute to food (24-27) and alcohol (28–30) seeking and consumption.”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [30]
In the citing paper
“The central nucleus of the amygdala (CeA) is critically involved in mediating negative emotional behaviors associated with alcohol dependence (Koob, 2021;Roberto et al., 2020).”
From Alcohol dependence and withdrawal increase sensitivity of central amygdalar GABAergic synapses to the glucocorticoid receptor antagonist mifepristone in male rats (2022) · cites this paper as Koob, 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Opposite directions reported for nociceptin during conditioned withdrawal
MinorThe review says conditioned opioid withdrawal increased nociceptin in the frontal cortex, but the cited study's title says it decreased nociceptin there.
“conditioned withdrawal (measured by place aversion) increased nociceptin levels (measured by a radioimmunoassay) in the frontal cortex (Walker et al., 2002).”
“Walker JR, Terenius L, and Koob GF (2002) Conditioned opioid withdrawal decreases nociceptin/orphanin FQ levels in the frontal cortex and olfactory tuber- cle.”
Opioid cost estimate is attributed to an alcohol-cost study
MinorThe order of "respectively" assigns the $179.4 billion estimate to opioid addiction, yet the cited Sacks study is titled as an estimate of alcohol-consumption costs. The attribution conflicts with the subject identified in the paper's own reference list.
“The annual costs to society in the United States of tobacco, alcohol, and opioid addiction are estimated to be $300 billion (https://www.cdc.gov/ drugoverdose/pdf/pubs/2019-cdc-drug-surveillance- report.pdf),$249 billion (https://www.drugabuse.gov/ related-topics/trends-statistics/overdose-death-rates), and $179.4 billion (Sacks et al., 2015), respectively.”
“Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, and Brewer RD (2015) 2010 Na- tional and state costs of excessive alcohol consumption.”
Citations
Cites
Items 401–579 of 579
Watanabe, T., Nakagawa, T., Yamamoto, R., Maeda, A., Minami, M., & Satoh, M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1504-0 · Cited by 71
Negus, S. S., & Rice, K. C. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.127 · Cited by 70 · cited 1×
“However, using this choice model, a study in rhesus monkeys failed to show positive effects with a CRF1 receptor antagonist (although one of three monkeys did respond) and a k-opioid receptor antagonist, but it did show positive results with opioid substitution drugs (Negus and Rice, 2009).”
MethodMedical safety and side effects of methadone in tolerant individuals
Kreek, M. J. (1973) · JAMA · doi:10.1001/jama.223.6.665 · Cited by 70
Chronic CRF1receptor blockade reduces heroin intake escalation and dependence‐induced hyperalgesia
Park, P. E., Schlosburg, J. E., Vendruscolo, L. F., Schulteis, G., Edwards, S., & Koob, G. F. (2015) · Addiction Biology · doi:10.1111/adb.12120 · Cited by 69
Self-citationGreenwell, T. N., Walker, B. M., Cottone, P., Zorrilla, E. P., & Koob, G. F. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.012 · Cited by 69
Self-citationA glutamatergic hypothesis of drug dependence
Stephens, D. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199508000-00004 · Cited by 69
Management of the Alcohol withdrawal Syndrome
Romach, M. K., & Sellers, E. M. (1991) · Annual Review of Medicine · doi:10.1146/annurev.me.42.020191.001543 · Cited by 69
Pain perception in drug-free and in methadone-maintained human ex-addicts
Ho, A., & Dole, V. P. (1979) · Experimental Biology and Medicine · doi:10.3181/00379727-162-40689 · Cited by 69
Macey, D. J., Koob, G. F., & Markou, A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02229-0 · Cited by 69
Self-citationFoidart, A., Harada, N., & Balthazart, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)90958-x · Cited by 69
(1968) · PubMed · Cited by 69
Karkhanis, A. N., Huggins, K. N., Rose, J. H., & Jones, S. R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.022 · Cited by 68
Lowery, E. G., Sparrow, A. M., Breese, G. R., Knapp, D. J., & Thiele, T. E. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00573.x · Cited by 68
Anderson, R. I., Lopez, M. F., Griffin, W. C., Haun, H. L., Bloodgood, D. W., Pati, D., Boyt, K. M., Kash, T. L., & Becker, H. C. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0294-3 · Cited by 68
Bailey, C. P., O'Callaghan, M. J., Croft, A. P., Manley, S. J., & Little, H. J. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00146-0 · Cited by 66
Predictors of alcohol use among people experiencing chronic pain
Lawton, J., & Simpson, J. (2009) · Psychology, Health & Medicine · doi:10.1080/13548500902923177 · Cited by 66
Cole, J. C., Littleton, J. M., & Little, H. J. (2000) · Psychopharmacology · doi:10.1007/s002130050009 · Cited by 65
The role of the vasopressin 1b receptor in aggression and other social behaviours
CALDWELL, H., WERSINGER, S., & YOUNGIII, W. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00406-8 · Cited by 64
CSF levels of norepinephrine during alcohol withdrawal
Hawley, R. J., Major, L. F., Schulman, E. A., & Lake, C. R. (1981) · Archives of Neurology · doi:10.1001/archneur.1981.00510050055008 · Cited by 64
Kallupi, M., Carrette, L. L. G., Kononoff, J., Solberg Woods, L. C., Palmer, A. A., Schweitzer, P., George, O., & de Guglielmo, G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915143117 · Cited by 64
Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal
Harris, A. C., & Gewirtz, J. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2155-0 · Cited by 63
Levran, O., Randesi, M., Li, Y., Rotrosen, J., Ott, J., Adelson, M., & Jeanne Kreek, M. (2014) · Annals of Human Genetics · doi:10.1111/ahg.12064 · Cited by 62
Waldrop, A. E., Santa Ana, E. J., Saladin, M. E., McRae, A. L., & Brady, K. T. (2007) · The American Journal on Addictions · doi:10.1080/10550490701643484 · Cited by 62
Lopez, M. F., Moorman, D. E., Aston-Jones, G., & Becker, H. C. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.049 · Cited by 62
Ethanol withdrawal and hyperalgesia
Gatch, M. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902010041 · Cited by 61
Moore, C. F., & Lynch, W. J. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.014 · Cited by 61
Nylander, I., Vlaskovska, M., & Terenius, L. (1995) · Psychopharmacology · doi:10.1007/bf02245939 · Cited by 61
Rorick-Kehn, L. M., Ciccocioppo, R., Wong, C. J., Witkin, J. M., Martinez-Grau, M. A., Stopponi, S., Adams, B. L., Katner, J. S., Perry, K. W., Toledo, M. A., et al. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13052 · Cited by 61
Similar anxiety-like responses in male and female rats exposed to repeated withdrawals from ethanol
Overstreet, D. H., Knapp, D. J., & Breese, G. R. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.04.018 · Cited by 60
Knapp, D. J., Whitman, B. A., Wills, T. A., Angel, R. A., Overstreet, D. H., Criswell, H. E., Ming, Z., & Breese, G. R. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.02.018 · Cited by 60 · cited 2×
“Injections of cytokines in the amygdala increased withdrawal-induced hyperkatifeialike responses, similar to exposure to stress or alcohol (Knapp et al., 2011).”
Backgroundvan der Schrier, R., Roozekrans, M., Olofsen, E., Aarts, L., van Velzen, M., de Jong, M., Dahan, A., & Niesters, M. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001505 · Cited by 60
Anderson, R. I., Lopez, M. F., & Becker, H. C. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4257-2 · Cited by 59
Drinking alcohol for medicinal purposes by people aged over 75: a community-based interview study
Aira, M., Hartikainen, S., & Sulkava, R. (2008) · Family Practice · doi:10.1093/fampra/cmn065 · Cited by 59
Pharmacological treatment of neuralgic and neuropathic pain.
Hj, M. (1988) · PubMed · Cited by 59
Massaly, N., Morón, J. A., & Al-Hasani, R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00480 · Cited by 59
Pati, D., Marcinkiewcz, C. A., DiBerto, J. F., Cogan, E. S., McElligott, Z. A., & Kash, T. L. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107759 · Cited by 59
Zhou, Y., Proudnikov, D., Yuferov, V., & Kreek, M. J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.015 · Cited by 58
Centanni, S. W., Bedse, G., Patel, S., & Winder, D. G. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14178 · Cited by 58 · cited 1×
“elements of negative affect and hyperkatifeia (Centanni et al., 2019).”
Zhou, Y., Colombo, G., Carai, M. A. M., Ho, A., Gessa, G. L., & Kreek, M. J. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01532.x · Cited by 57
Interaction between des-Glycinamide9-[ARG8]vasopressin and serotonin on ethanol tolerance
Lê, A. D., Kalant, H., & Khanna, J. M. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90079-6 · Cited by 57
Laorden, M. L., Ferenczi, S., Pintér-Kübler, B., González-Martín, L. L., Lasheras, M. C., Kovács, K. J., Milanés, M. V., & Núñez, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036871 · Cited by 55
Zhou, Y., Leri, F., Grella, S. L., Aldrich, J. V., & Kreek, M. J. (2013) · Synapse · doi:10.1002/syn.21638 · Cited by 55
The oxytocin receptor impairs ethanol reward in mice
Bahi, A. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.11.046 · Cited by 55
Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction
Clarke, T. ‐., Ambrose‐Lanci, L., Ferraro, T. N., Berrettini, W. H., Kampman, K. M., Dackis, C. A., Pettinati, H. M., O’Brien, C. P., Oslin, D. W., & Lohoff, F. W. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00785.x · Cited by 55
Thorsell, A., Slawecki, C. J., & Ehlers, C. L. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000160084.13148.02 · Cited by 54
Alcohol reinforcement and neuropharmacological therapeutics
LEWIS, M. J. (1996) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a008214 · Cited by 54
Culpepper-Morgan, J. A., & Kreek, M. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90289-4 · Cited by 54
Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal
Kosten, T. A. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90370-0 · Cited by 54
Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors
Woldbye, D. P. D., Klemp, K., & Madsen, T. M. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37249-0 · Cited by 54
Gene expression changes following extinction testing in a heroin behavioral incubation model
Kuntz-Melcavage, K. L., Brucklacher, R. M., Grigson, P. S., Freeman, W. M., & Vrana, K. E. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-95 · Cited by 53
Oxytocin attenuates stress-induced reinstatement of alcohol seeking behavior in male and female mice
King, C. E., & Becker, H. C. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05233-z · Cited by 53
Kovács, G. L., Izbéki, F., Horváth, Z., & Telegdy, G. (1984) · Behavioural Brain Research · doi:10.1016/0166-4328(84)90014-7 · Cited by 53
Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals
Carcoba, L. M., Contreras, A. E., Cepeda-Benito, A., & Meagher, M. W. (2011) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.581985 · Cited by 52
Moeini, M., Omidi, A., Sehat, M., & Banafshe, H. R. (2019) · European Addiction Research · doi:10.1159/000496194 · Cited by 52
Effects of NMDA antagonists on ethanol-withdrawal induced “anxiety” in the elevated plus maze
Gatch, M. B., Wallis, C. J., & Lal, H. (1999) · Alcohol · doi:10.1016/s0741-8329(99)00045-2 · Cited by 51
Kalange, A. S., Kokare, D. M., Singru, P. S., Upadhya, M. A., Chopde, C. T., & Subhedar, N. K. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.054 · Cited by 50
Bajo, M., Madamba, S. G., Roberto, M., Blednov, Y. A., Sagi, V. N., Roberts, E., Rice, K. C., Harris, R. A., & Siggins, G. R. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.03.007 · Cited by 49
Heroin addiction engages negative emotional learning brain circuits in rats
Carmack, S. A., Keeley, R. J., Vendruscolo, J. C. M., Lowery‐Gionta, E. G., Lu, H., Koob, G. F., Stein, E. A., & Vendruscolo, L. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125534 · Cited by 49
Self-citationAn opponent-process theory of motivation: III. Some affective dynamics in imprinting
Hoffman, H. S., & Solomon, R. L. (1974) · Learning and Motivation · doi:10.1016/0023-9690(74)90022-8 · Cited by 48
Johnstone, L. E., Brown, C. H., Meeren, H. K. M., Vuijst, C. L., Brooks, P. J., Leng, G., & Russell, J. A. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-03-01272.2000 · Cited by 48
Moreton, J. E., Roehrs, T., & Khazan, N. (1976) · Psychopharmacology · doi:10.1007/bf00427607 · Cited by 48
Perney, P., Lehert, P., & Mason, B. J. (2012) · Alcohol and Alcoholism · doi:10.1093/alcalc/agr160 · Cited by 48
Manwell, L. A., Satvat, E., Lang, S. T., Allen, C. P., Leri, F., & Parker, L. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.002 · Cited by 48
Stopponi, S., Fotio, Y., Domi, A., Borruto, A. M., Natividad, L., Roberto, M., Ciccocioppo, R., & Cannella, N. (2018) · Addiction Biology · doi:10.1111/adb.12573 · Cited by 48
Chronic pain alters drug self-administration: Implications for addiction and pain mechanisms.
Martin, T. J., & Ewan, E. E. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013597 · Cited by 47
Dynorphin and its role in alcohol use disorder
Karkhanis, A. N., & Al-Hasani, R. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146742 · Cited by 47
Kang, S., Li, J., Zuo, W., Chen, P., Gregor, D., Fu, R., Han, X., Bekker, A., & Ye, J.-H. (2019) · Scientific Reports · doi:10.1038/s41598-018-38393-7 · Cited by 47
Morris, L. E., Knott, J. R., & Pittinger, C. B. (1955) · Anesthesiology · doi:10.1097/00000542-195505000-00003 · Cited by 45
Harris, A. C., Pentel, P. R., Burroughs, D., Staley, M. D., & LeSage, M. G. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2273-9 · Cited by 44
Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors
Frye, C. A., Walf, A. A., & Sumida, K. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.04.014 · Cited by 44
Franklin, K. M., Hauser, S. R., Lasek, A. W., McClintick, J., Ding, Z.-M., McBride, W. J., & Bell, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3852-3 · Cited by 44
Watanabe, T., Yamamoto, R., Maeda, A., Nakagawa, T., Minami, M., & Satoh, M. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03468-6 · Cited by 44 · cited 1×
“Excitotoxic lesions of the CeA blocked the development of morphine withdrawal– induced conditioned place aversion but had less of an effect on somatic signs of withdrawal (Watanabe et al., 2002).”
BackgroundAlcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse.
Besemer, F., Pereira, A. M., & Smit, J. W. A. (2011) · PubMed · Cited by 43
Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors
Hummel, M., Cummons, T., Lu, P., Mark, L., Harrison, J. E., Kennedy, J. D., & Whiteside, G. T. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.001 · Cited by 43
Walter, M., Gerber, H., Kuhl, H. C., Schmid, O., Joechle, W., Lanz, C., Brenneisen, R., Schächinger, H., Riecher-Rössler, A., Wiesbeck, G. A., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828393cb · Cited by 43
Salivary cortisol during opiate dependence and withdrawal
Bearn, J., Buntwal, N., Papadopoulos, A., & Checkley, S. (2001) · Addiction Biology · doi:10.1080/13556210020040235 · Cited by 42
Kovács, G. L., & van Ree, J. M. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90007-4 · Cited by 42
Lopez, M. F., Grahame, N. J., & Becker, H. C. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01426.x · Cited by 41
Roltsch Hellard, E. A., Impastato, R. A., & Gilpin, N. W. (2017) · Addiction Biology · doi:10.1111/adb.12360 · Cited by 41
Mesenchymal Stem Cells Reversed Morphine Tolerance and Opioid-induced Hyperalgesia
Hua, Z., Liu, L., Shen, J., Cheng, K., Liu, A., Yang, J. F., Wang, L., Qu, T., Yang, H., Li, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep32096 · Cited by 41
Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice
Gamage, T. F., Ignatowska-Jankowska, B. M., Muldoon, P. P., Cravatt, B. F., Damaj, M. I., & Lichtman, A. H. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.11.015 · Cited by 40 · cited 1×
“However, in mice, an FAAH inhibitor and an MAGL inhibitor blocked somatic signs of precipitated opioid withdrawal in mice (Gamage et al., 2015), but they failed to block naloxone-precipitated withdrawal-induced place aversion.”
BackgroundReilly, W., Koirala, B., & Devaud, L. L. (2009) · Alcohol and Alcoholism · doi:10.1093/alcalc/agp049 · Cited by 40
Clonidine maintains intrathecal self-administration in rats following spinal nerve ligation
Martin, T. J., Kim, S. A., & Eisenach, J. C. (2006) · Pain · doi:10.1016/j.pain.2006.05.027 · Cited by 40
Podlesnik, C. A., Ko, M.-C., Winger, G., Wichmann, J., Prinssen, E. P., & Woods, J. H. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2012-7 · Cited by 40
Expression of pronociceptin and its receptor is downregulated in the brain of human alcoholics
Kuzmin, A., Bazov, I., Sheedy, D., Garrick, T., Harper, C., & Bakalkin, G. (2009) · Brain Research · doi:10.1016/j.brainres.2009.05.067 · Cited by 40
Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat
Riihioja, P., Jaatinen, P., Oksanen, H., Haapalinna, A., Heinonen, E., & Hervonen, A. (1997) · Alcohol · doi:10.1016/s0741-8329(97)00044-x · Cited by 40 · cited 1×
“Subsequent studies have shown that a2-adrenergic agonists decrease somatic signs of alcohol withdrawal in animal models (Parale and Kulkarni, 1986; Riihioja et al., 1997), including responses that are associated with hyperkatifeia, such as the clonidine-induced blockade of anxiogenic-like effects…”
BackgroundChronic pain causes a persistent anxiety state leading to increased ethanol intake in CD1 mice
González-Sepúlveda, M., Pozo, O. J., Marcos, J., & Valverde, O. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115622238 · Cited by 40
Receptors with V1 characteristics mediate the maintenance of ethanol tolerance by vasopressin
Szabó, G., Tabakoff, B., & Hoffman, P. L. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13397-1 · Cited by 40
Days With Pain and Substance Use Disorders: Is There an Association?
Edlund, M. J., Sullivan, M. D., Han, X., & Booth, B. M. (2013) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e318270fa77 · Cited by 39
Negus, S. S., Zuzga, D. S., & Mello, N. K. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.124734 · Cited by 39
Solecki, W., Ziolkowska, B., Krowka, T., Gieryk, A., Filip, M., & Przewlocki, R. (2009) · Brain Research · doi:10.1016/j.brainres.2008.12.002 · Cited by 39 · cited 2×
“Expression of the dynorphin precursor prodynorphin is also increased during the anticipation of heroin (Cappendijk et al., 1999) and after heroin self-administration (Solecki et al., 2009).”
BackgroundTask difficulty increases thresholds of rewarding brain stimulation
Fouriezos, G., Bielajew, C. H., & Pagotto, W. (1990) · Behavioural Brain Research · doi:10.1016/0166-4328(90)90066-n · Cited by 39
Epigenetics of Addiction: Current Knowledge, Challenges, and Future Directions
Cecil, C. A. M., Walton, E., & Viding, E. M. (2016) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2016.77.688 · Cited by 39
Ahmed, S. H. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.005 · Cited by 39
Bagdas, D., Muldoon, P. P., AlSharari, S., Carroll, F. I., Negus, S. S., & Damaj, M. I. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.11.024 · Cited by 39
Hwa, L., Besheer, J., & Kash, T. (2017) · F1000Research · doi:10.12688/f1000research.9609.1 · Cited by 39
Shumilla, J. A., Liron, T., Mochly-Rosen, D., Kendig, J. J., & Sweitzer, S. M. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2005.03.005 · Cited by 38
Studies with {? 2}-adrenoceptor agonists and alcohol abstinence syndrome in rats
Parale, M. P., & Kulkarni, S. K. (1986) · Psychopharmacology · doi:10.1007/bf00652247 · Cited by 38
Simms, J. A., Nielsen, C. K., Li, R., et al. (2013) · Addiction Biology · doi:10.1111/adb.12024 · Cited by 37
Murphy, N. P., Onaka, T., Brown, C. H., & Leng, G. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00142-5 · Cited by 37
Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats
Schulteis, G. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00036-0 · Cited by 37
Zhou, Y., Colombo, G., Gessa, G. L., & Kreek, M. J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.08.071 · Cited by 36
A Comparison of Methods for Estimating Change in Drinking following Alcohol Treatment
Witkiewitz, K. A., Maisto, S. A., & Donovan, D. M. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01308.x · Cited by 36
Kelsey, J. E., Verhaak, A. M. S., & Schierberl, K. C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.008 · Cited by 36
Célérier, E., Simonnet, G., & Maldonado, R. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.08.008 · Cited by 36 · cited 1×
“Given that protein kinase C (PKC) regulates NMDA receptors, opioid-induced hyperalgesia was also reduced in PKCg gene knockout mice (Célèrier et al., 2004).”
BackgroundKuikka, J. T., Repo, E., Bergström, K. A., Tupala, E., & Tiihonen, J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01423-3 · Cited by 35
Declining efficacy in controlled trials of antidepressants: effects of placebo dropout
Schalkwijk, S., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000224 · Cited by 34
Brown, C. H., & Russell, J. A. (2004) · Stress · doi:10.1080/10253890410001727776 · Cited by 34
Negus, S. S., & Banks, M. L. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.04.006 · Cited by 34
Shen, N., Mo, L., Hu, F., et al. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12244 · Cited by 34
Diaz, S. L., Kemmling, A. K., Rubio, M. C., & Balerio, G. N. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.10.012 · Cited by 34
Sukhtankar, D. D., Lagorio, C. H., & Ko, M.-C. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.029 · Cited by 33
Maric, T., Tobin, S., Quinn, T., & Shalev, U. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.023 · Cited by 33
Melby, K., Gråwe, R. W., Aamo, T. O., Salvesen, Ø., & Spigset, O. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.003 · Cited by 33
Defining the role of corticotropin releasing factor binding protein in alcohol consumption
Haass-Koffler, C. L., Henry, A. T., Melkus, G., Simms, J. A., Naemmuddin, M., Nielsen, C. K., Lasek, A. W., Magill, M., Schwandt, M. L., Momenan, R., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.208 · Cited by 33
Lee, M. R., Schwandt, M. L., Sankar, V., Suchankova, P., Sun, H., & Leggio, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.07.481 · Cited by 33
Engin, E., & Treit, D. (2008) · Neuropeptides · doi:10.1016/j.npep.2008.04.004 · Cited by 32
Alvarez-Jaimes, L., Polis, I., & Parsons, L. H. (2009) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523800902020077 · Cited by 32
Orphanin FQ/nociceptin inhibits morphine withdrawal
Kotlińska, J., Suder, P., Legowska, A., Rolka, K., & Silberring, J. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00648-7 · Cited by 31
Alpha-2-adrenoceptor sensitivity in early alcohol withdrawal
Balldin, J., Berggren, U., Engel, J. A., et al. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90281-4 · Cited by 31
Morphine withdrawal increases intrinsic excitability of oxytocin neurons in morphine‐dependent rats
Brown, C. H., Stern, J. E., Jackson, K., Bull, P. M., Leng, G., & Russell, J. A. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03885.x · Cited by 31
Puciklowski, O., Kostowski, W., & Trzaskowska, E. (1985) · Peptides · doi:10.1016/0196-9781(85)90067-1 · Cited by 29
The effect of clonidine and related substances on voluntary ethanol consumption in rats.
Opitz, K. (1990) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(90)90139-6 · Cited by 29
D'Amato, M. R. (1974) · Annual Review of Psychology · doi:10.1146/annurev.ps.25.020174.000503 · Cited by 29
Mingione, C. J., Heffner, J. L., Blom, T. J., & Anthenelli, R. M. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.11.013 · Cited by 29
Wills, K. L., Vemuri, K., Kalmar, A., Lee, A., Limebeer, C. L., Makriyannis, A., & Parker, L. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3575-5 · Cited by 29
Sugiura, H., Tanaka, H., Yasuda, S., Takemiya, T., & Yamagata, K. (2009) · The Neuroscientist · doi:10.1177/1073858408324024 · Cited by 27
Jodogne, C., Tirelli, E., Klingbiel, P., & Legros, J.-J. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90549-h · Cited by 27
Nader, K., & van der Kooy, D. (1996) · Behavioral Neuroscience · doi:10.1037/0735-7044.110.2.389 · Cited by 27
Svirshchevskaya, E. V., Frolova, E., Alekseeva, L. G., et al. (2000) · Peptides · doi:10.1016/s0196-9781(99)00173-4 · Cited by 27
Rasmussen, D. D., Alexander, L., Malone, J., Federoff, D., & Froehlich, J. C. (2014) · Alcohol · doi:10.1016/j.alcohol.2014.07.002 · Cited by 26
Effects of methadone and morphine maintenance on drug-seeking behavior in the dog
Jones, B. E., & Prada, J. A. (1977) · Psychopharmacology · doi:10.1007/bf00426764 · Cited by 26
The Role of Arginine Vasopressin in Alcohol Tolerance
Hoffman, P. L., Ishizawa, H., Giri, P. R., Dave, J. R., Grant, K. A., Liu, L.-L., Gulya, K., & Tabakoff, B. (1990) · Annals of Medicine · doi:10.3109/07853899009148939 · Cited by 26
Cappendijk, S. L. T., Hurd, Y. L., Nylander, I., van Ree, J. M., & Terenius, L. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00874-7 · Cited by 25
Nader, K., & van der Kooy, D. (1996) · Behavioral Neuroscience · doi:10.1037//0735-7044.110.2.389 · Cited by 25
Hata, T., Chen, J., Ebihara, K., Date, Y., Ishida, Y., & Nakahara, D. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07808.x · Cited by 25
Wills, K. L., Petrie, G. N., Millett, G., Limebeer, C. L., Rock, E. M., Niphakis, M. J., Cravatt, B. F., & Parker, L. A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.356 · Cited by 25
Gallo, A., Gonzalez-Lima, F., & Sadile, A. G. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00427-2 · Cited by 24
Alizadeh, M., Khorasani, M. Z., & Miladi‐Gorji, H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.044 · Cited by 24
Clausen, T. R., Møller, M., & Woldbye, D. P. D. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1092 · Cited by 24
Berggren, U. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00051-4 · Cited by 23
Laska, E. M., Siegel, C. E., Lin, Z., Bogenschutz, M., & Marmar, C. R. (2020) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14414 · Cited by 23
Differential effects of heroin on opioid levels in the rat brain
Weissman, B. A., & Zamir, N. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90506-1 · Cited by 22
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence
Okahisa, Y., Ujike, H., Kotaka, T., Morita, Y., Kodama, M., Inada, T., Yamada, M., Iwata, N., Iyo, M., Sora, I., et al. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01961.x · Cited by 21
Further studies on the role of noradrenergic mechanisms in ethanol withdrawal syndrome in rats.
Trzaskowska, E., & Kostowski, W. (1984) · PubMed · Cited by 20
A mouse model for chronic pain-induced increase in ethanol consumption
Butler, R. K., Knapp, D. J., Ulici, V., Longobardi, L., Loeser, R. F., & Breese, G. R. (2017) · Pain · doi:10.1097/j.pain.0000000000000780 · Cited by 20
Bhaskar, L. V., Thangaraj, K., Kumar, K., et al. (2013) · European Addiction Research · doi:10.1159/000346679 · Cited by 19
Domokos, Á., Mergl, Z., Barna, I., Makara, G. B., & Zelena, D. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0356 · Cited by 19
Yang, L., Wang, F., Wang, M., Han, M., Hu, L., Zheng, M., Ma, J., Kang, Y., Wang, P., Sun, H., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.066 · Cited by 19 · cited 1×
“A polymorphism of the oxytocin gene, rs6133010, was associated with alcohol dependence in a northern Chinese Han population (Yang et al., 2017).”
BackgroundTirelli, E., Jodogne, C., & Legros, J.-J. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90512-e · Cited by 18
Nikolaou, K., Kapoukranidou, D., Ndungu, S., Floros, G., & Kovatsi, L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312644 · Cited by 18
Mutschler, J., Abbruzzese, E., von der Goltz, C., Dinter, C., Mobascher, A., Thiele, H., Diaz-Lacava, A., Dahmen, N., Gallinat, J., Majic, T., et al. (2012) · European Addiction Research · doi:10.1159/000338276 · Cited by 17
Zuo, W., Wu, L., Mei, Q., Zuo, Q., Zhou, Z., Fu, R., Li, W., Wu, W., Matthew, L., & Ye, J.-H. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107747 · Cited by 17
Effect of histone deacetylase inhibitor on ethanol withdrawal-induced hyperalgesia in rats
Pradhan, A. A., Tipton, A. F., Zhang, H., Akbari, A., & Pandey, S. C. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz031 · Cited by 16
ETHICS, FUNDING AND ALCOHOL RESEARCH
PLANT, M., PLANT, M., PLANT, M., et al. (1996) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a008112 · Cited by 15
Alcohol Misuse and Abuse among the Elderly
Lamy, P. P. (1984) · Annals of Pharmacotherapy · doi:10.1177/106002808401800731 · Cited by 14
Opioids and Suicide: Opportunities for Comprehensive Prevention
Ranade, R., Wunder, J., Terzian, M., & Ungureanu, I. (2020) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000001161 · Cited by 14
Cohen, I. M., Fischer, J. F., & Vogel, W. H. (1974) · Psychopharmacology · doi:10.1007/bf00441384 · Cited by 13
Walker, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00292-0 · Cited by 13
Thullier, F., Lalonde, R., & Lestienne, F. G. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00228-7 · Cited by 12
The effect of prolonged ethanol administration on central alpha 2-adrenoceptors sensitivity.
Szmigielski, A., Szmigielska, H., & Wejman, I. (1990) · PubMed · Cited by 12
Kotlinska, J., Dylag, T., Rafalski, P., Talarek, S., Kosior, M., & Silberring, J. (2004) · Neuropeptides · doi:10.1016/j.npep.2004.05.001 · Cited by 11
Changes in oxytocin content in rat brain during morphine withdrawal
Laorden, M. L., Milanés, M. V., Chapleur-Château, M., & Burlet, A. (1998) · Neuropeptides · doi:10.1016/s0143-4179(98)90019-1 · Cited by 10 · cited 1×
“Increases in oxytocin content in the PVN and median eminence were observed during naloxoneprecipitated morphine withdrawal (Laorden et al., 1998).”
BackgroundArora, S., & Vohora, D. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12566 · Cited by 9
Young, G. A., Steinfels, G. F., & Khazan, N. (1978) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(78)90081-9 · Cited by 7
Masten, L. W., Hine, C. H., & Way, E. L. (1978) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(78)90013-3 · Cited by 6
Szabó, G., Kovács, G. L., Baláspiri, L., & Telegdy, G. (1987) · PubMed · Cited by 6
Dissecting compulsive eating behavior into three elements
Moore, C. F., Sabino, V., Koob, G. F., & Cottone, P. (2019) · Compulsive Eating Behavior and Food Addiction · doi:10.1016/b978-0-12-816207-1.00003-2 · Cited by 4
Self-citationThe effect of acetaldehyde-glycosaminoglycan mixtures upon Factor IXa and Factor IX-Deficient Plasma
Brecher, A. S., Moon, A. R., & Gray, K. D. (2006) · Alcohol · doi:10.1016/j.alcohol.2006.08.005 · Cited by 3
Massaly, N. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.02.045 · Cited by 3
Family Planning: A Growing Gap
Holden, C. (1988) · Science · doi:10.1126/science.3175659 · Cited by 1
Complex Rare Variation and Its Role in Endophenotypic Variation in Schizophrenia
Blangero, J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.028 · Cited by 1
Advice and information from a former editor
Barry, H. (1992) · Psychopharmacology · doi:10.1007/bf02245107 · Cited by 1
Wills, K. L., Vemuri, K. V., Kalmar, A., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3692-1
Veinante, P., & Freund-Mercier, M.-J. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19970707)383:3
208. Corticotropin releasing factor, stress and allostasis
Koob, G. F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00471-6
Self-citationHua, Z., Liu, L., Shen, J., Cheng, K., Liu, A., Yang, J., Wang, L., Qu, T., Yang, H., Li, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep40978
NPY signaling inhibits extended amygdala CRF neurons to suppress binge alcohol drinking
Pleil, K. E., Rinker, J. A., Lowery-Gionta, E. G., Mazzone, C. M., McCall, N. M., Kendra, A. M., Olson, D. P., Lowell, B. B., Grant, K. A., Thiele, T. E., et al. (2016) · Neuropeptides · doi:10.1016/j.npep.2015.11.009
Sex differences in animal models: Focus on stress and addiction
Becker, J. B. (2017) · Alcohol · doi:10.1016/j.alcohol.2017.02.186
Flagged first, then by citations
Research works printed but not linked: 1
- Himmelsbach, 1943, Can the euphoric, analgetic, and physical dependence effects of drugs be separated? IV. With reference to physical dependence, Fed Proc, 2, 201
Cited by
Sorted by citations
Consequences of adolescent drug use
Steinfeld, M. R., & Torregrossa, M. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02590-4 · Cited by 237
“Many theories have been proposed, including dysregulation of the mesolimbic reward system [129], loss of goal-directed control [246], and hyperkaite fi a [247], but other mechanisms are likely at work.”
BackgroundChuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Self-citationTowers, E. B., Williams, I. L., Qillawala, E. I., Rissman, E. F., & Lynch, W. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000361 · Cited by 157
Alcohol and the brain: from genes to circuits
Egervári, G., Siciliano, C. A., Whiteley, E. L., & Dorit Ron, A. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.09.006 · Cited by 128
The Incentive-Sensitization Theory of Addiction 30 Years On
Robinson, T. E., & Berridge, K. C. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-011624-024031 · Cited by 146
“Seeking relief from distress is in a sense analogous to the aversive escape logic of opponent process theories (Solomon & Corbit 1974, Koob 2021).”
Influential
Metadata
- Authors
- Koob, G. F.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Koob, George F.
- ORCID
- Koob, George F.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 73
- Issue
- 1
- Pages
- 163-201
- ISSN
- 0031-6997 (ISSN-L)
- PMC
- PMC7770492
- OpenAlex
- W3112790012
- Cited by
- 337
- References
- 577
- Citations by year
- 2026: 63 · 2025: 60 · 2024: 65 · 2023: 56 · 2022: 63 · 2021: 29
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Pharmacological Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- drug addiction, negative reinforcement, compulsive drug seeking, drug withdrawal, negative affect, extended amygdala, habenula, basal ganglia, executive function, incentive salience, dopamine, opioid peptides, corticotropin-releasing factor, glucocorticoids, dynorphin, orexin, nociceptin, endocannabinoid system, oxytocin, allostatic load
- MeSH terms
- Drug Development, Humans, Motivation, Reinforcement, Psychology, Reward, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review